Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Benzodiazepines and Other Targeted Substances Regulations (SOR/2000-217)

Regulations are current to 2020-05-17 and last amended on 2019-12-09. Previous Versions

Benzodiazepines and Other Targeted Substances Regulations

SOR/2000-217

CONTROLLED DRUGS AND SUBSTANCES ACT

Registration 2000-06-01

Benzodiazepines and Other Targeted Substances Regulations

P.C. 2000-827  2000-06-01

Her Excellency the Governor General in Council, on the recommendation of the Minister of Health, pursuant to subsection 55(1) of the Controlled Drugs and Substances ActFootnote a, hereby makes the annexed Benzodiazepines and Other Targeted Substances Regulations (1091).

Interpretation

Marginal note:Definitions

 The following definitions apply in these Regulations.

Act

Act means the Controlled Drugs and Substances Act. (Loi)

adult

adult means an individual of 18 years of age or older. (adulte)

advertisement

advertisement, in respect of a targeted substance, includes any representation by any means for the purpose of promoting, directly or indirectly, the sale or other disposal of the targeted substance. (publicité)

common-law partner

common-law partner in relation to an individual, means a person who is cohabiting with the individual in a conjugal relationship, having so cohabited for a period of at least one year. (conjoint de fait)

competent authority

competent authority means a public authority of a foreign country that is authorized under the laws of the country to approve the importation or exportation of targeted substances into or from the country. (autorité compétente)

Department

Department[Repealed, SOR/2019-170, s. 1]

designated criminal offence

designated criminal offence means

  • (a) an offence involving the financing of terrorism against any of sections 83.02 to 83.04 of the Criminal Code;

  • (b) an offence involving fraud against any of sections 380 to 382 of the Criminal Code;

  • (c) the offence of laundering proceeds of crime against section 462.31 of the Criminal Code;

  • (d) an offence involving a criminal organization against any of sections 467.11 to 467.13 of the Criminal Code; or

  • (e) a conspiracy or an attempt to commit, being an accessory after the fact in relation to, or any counselling in relation to, an offence referred to in any of paragraphs (a) to (d). (infraction désignée en matière criminelle)

designated drug offence

designated drug offence[Repealed, SOR/2019-170, s. 1]

destroy

destroy, in respect of a targeted substance, means to alter or denature it to such an extent that its consumption is rendered impossible or improbable. (destruction)

emergency medical service vehicle

emergency medical service vehicle means any conveyance authorized under the laws of a province to transport individuals to hospitals and on which emergency medical services are provided. (véhicule de service médical d’urgence)

export permit

export permit[Repealed, SOR/2019-170, s. 1]

hospital

hospital means a facility that

  • (a) is licensed, approved or designated as a hospital by a province under the laws of the province to provide health care or treatment to persons or animals; or

  • (b) is owned or operated by the government of Canada or of a province and that provides health services. (hôpital)

import permit

import permit[Repealed, SOR/2019-170, s. 1]

international obligation

international obligation means an obligation relative to a targeted substance set out in a convention, treaty or other multilateral or bilateral instrument that Canada has ratified or to which Canada adheres. (obligation internationale)

licensed dealer

licensed dealer means the holder of a licence issued under section 17.1. (distributeur autorisé)

midwife

midwife has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (sage-femme)

nurse practitioner

nurse practitioner has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (infirmier praticien)

package

package[Repealed, SOR/2019-170, s. 1]

pharmacist

pharmacist means a person who is entitled under the laws of a province to practise pharmacy and is practising pharmacy in that province. (pharmacien)

podiatrist

podiatrist has the same meaning as in section 1 of the New Classes of Practitioners Regulations. (podiatre)

prescription

prescription means an authorization given by a practitioner that a stated amount of a targeted substance be dispensed for the person named in it or the animal identified in it. (ordonnance)

qualified person in charge

qualified person in charge means the individual designated under subsection 15(1). (responsable qualifié)

Security Directive

Security Directive means the Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis, as amended from time to time and published by the Government of Canada on its website. (Directive en matière de sécurité)

senior person in charge

senior person in charge means the individual designated under section 14. (responsable principal)

specified name

specified name means, in respect of a controlled substance included in Schedule 1,

  • (a) the name specified in column 1 of an item of Schedule 2, but, if only the chemical name is specified, means the chemical name specified in column 2 of that item; or

  • (b) if the controlled substance is not specified in Schedule 2, its chemical name and, if available, its common name. (nom spécifié)

targeted substance

targeted substance means

  • (a) a controlled substance set out in Schedule 1; or

  • (b) in respect of a midwife, nurse practitioner or podiatrist, a controlled substance set out in Schedule 1 that the midwife, nurse practitioner or podiatrist may prescribe, possess or conduct an activity with, in accordance with section 3 of the New Classes of Practitioners Regulations. (substance ciblée)

test kit

test kit means a kit

  • (a) that contains a targeted substance and a reagent system or buffering agent;

  • (b) that is used during the course of a chemical or analytical procedure to test for the presence or quantity of a targeted substance for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose; and

  • (c) the contents of which are not intended or likely to be consumed by, or administered to, a person or an animal. (nécessaire d’essai)

transhipment

transhipment[Repealed, SOR/2019-170, s. 1]

  • SOR/2003-38, s. 2
  • SOR/2010-223, s. 1
  • SOR/2012-230, s. 25
  • SOR/2018-147, s. 30
  • SOR/2019-170, s. 1

Non-application

Marginal note:Member of police force

 A member of a police force or a person acting under their direction and control who, in respect of the conduct of the member or person, is exempt from the application of subsection 4(2) or section 5, 6 or 7 of the Act by virtue of the Controlled Drugs and Substances Act (Police Enforcement) Regulations is, in respect of that conduct, exempt from the application of these Regulations.

  • SOR/2010-223, s. 2(E)
  • SOR/2019-170, s. 2

Possession

Marginal note:Authorized persons

  •  (1) A person is authorized to possess a targeted substance set out in Part 2 of Schedule 1 if the person has obtained the targeted substance in accordance with these Regulations, in the course of activities conducted in connection with the administration or enforcement of an Act or regulation, or from a person who is exempt under section 56 of the Act from the application of subsection 5(1) of the Act with respect to that targeted substance, and the person

    • (a) requires the targeted substance for their business or profession and is

      • (i) a licensed dealer,

      • (ii) a pharmacist, or

      • (iii) a practitioner who is registered and entitled to practise in the province in which they possess the targeted substance;

    • (b) is a practitioner who is registered and entitled to practise in a province other than the province in which they possess the targeted substance for emergency medical purposes only;

    • (c) is a hospital employee or a practitioner in a hospital;

    • (d) has obtained the targeted substance for their own use or the use of another person for whom, or an animal for which, they are responsible

      • (i) from a practitioner, or

      • (ii) in accordance with a prescription that was not issued or obtained in contravention of these Regulations;

    • (e) is employed as an inspector, a member of the Royal Canadian Mounted Police, a police constable, a peace officer or a member of the technical or scientific staff of the Government of Canada, the government of a province or a university in Canada and their possession is in connection with that employment;

    • (f) is exempt under section 56 of the Act with respect to the possession of that targeted substance and their possession is for a purpose set out in the exemption;

    • (g) has imported the targeted substance in accordance with section 68 for their own use or the use of another person for whom, or an animal for which, they are responsible;

    • (h) is a person who, in accordance with a permit for transit or transhipment, is responsible for the targeted substance while it is in transit or in transhipment in Canada; or

    • (i) is the Minister.

  • Marginal note:Agent or mandatary

    (2) A person is authorized to possess a targeted substance set out in Part 2 of Schedule 1 if the person is acting as the agent or mandatary of any person who is authorized to possess it in accordance with any of paragraphs (1)(a) to (d) and (f) to (h).

  • Marginal note:Agent or mandatary — person referred to in paragraph (1)(e)

    (3) A person is authorized to possess a targeted substance set out in Part 2 of Schedule 1 if they

    • (a) are acting as the agent or mandatary of a person who they have reasonable grounds to believe is a person referred to in paragraph (1)(e); and

    • (b) possess the targeted substance for the purpose of assisting that person in the administration or enforcement of an Act or regulation.

  • Marginal note:Export by individual

    (4) An individual may possess a targeted substance set out in Part 2 of Schedule 1 for the purpose of exporting that substance in accordance with section 69.

  • SOR/2019-170, s. 2

Test Kits

Marginal note:Authorized activities

 A person may sell, possess or otherwise deal in a test kit if the following conditions are met:

  • (a) a registration number has been issued for the test kit under section 6 or subsection 10(2) and has not been cancelled under subsection 9(1);

  • (b) the test kit is labelled with

    • (i) the registration number, and

    • (ii) in the case of a test kit that is not subject to the labelling requirements of the Medical Devices Regulations,

      • (A) the name and address of the manufacturer or assembler or, if the test kit is manufactured or assembled in accordance with a custom order, the name and address of the person for whom the test kit was manufactured or assembled, and

      • (B) its brand name; and

  • (c) the test kit will be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

  • SOR/2010-223, s. 3(F)
  • SOR/2018-69, s. 78(E)
  • SOR/2019-170, s. 2

Marginal note:Application for registration number

  •  (1) The manufacturer or assembler of a test kit or, if the test kit is manufactured or assembled in accordance with a custom order, the person for whom the test kit was manufactured or assembled, may obtain a registration number for the test kit by submitting to the Minister an application containing

    • (a) the brand name of the test kit;

    • (b) a detailed description of the design and construction of the test kit;

    • (c) a detailed description of the targeted substance and other substances, if any, contained in the test kit, including

      • (i) the specified name of the targeted substance and the name of any other substance,

      • (ii) if the substance is a salt, the name of the salt, and

      • (iii) the quantity of the substance;

    • (d) a description of the proposed use of the test kit; and

    • (e) the directions for use of the test kit.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the person authorized by the applicant for that purpose; and

    • (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge.

  • Marginal note:Additional information and documents

    (3) The applicant must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2019-170, s. 2

Marginal note:Issuance of registration number

 Subject to section 7, on completion of the review of the application for a registration number, the Minister must issue a registration number for the test kit, preceded by the letters “TK”, if the Minister determines that the test kit will only be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

  • SOR/2019-170, s. 2

Marginal note:Refusal of registration number

  •  (1) The Minister must refuse to issue a registration number for a test kit if the Minister has reasonable grounds to believe that

    • (a) the test kit poses a risk to public health or safety, including the risk of the targeted substance in the test kit being diverted to an illicit market or use, because

      • (i) the total amount of the targeted substance in the test kit is too high, or

      • (ii) the adulterating or denaturing agent in the test kit is not likely to prevent or deter the consumption of the targeted substance in the test kit by a person or animal or the administration of that substance to a person or animal; or

    • (b) the test kit is likely to be used for a purpose other than one referred to in section 6.

  • Marginal note:Notice

    (2) Before refusing to issue a registration number, the Minister must send the applicant a notice that sets out the Minister’s reasons and gives the applicant an opportunity to be heard.

  • SOR/2019-170, s. 2

Marginal note:Labelling — non-application

 The symbol required by subparagraph C.01.004(1)(b)(iv) of the Food and Drug Regulations does not need to appear on the label of a test kit if the label displays the registration number that has been issued for the test kit under section 6 or subsection 10(2).

  • SOR/2019-170, s. 2

Marginal note:Cancellation of registration number

  •  (1) The Minister must cancel the registration number of a test kit if

    • (a) the Minister receives a notice from the holder of the registration number stating that they have ceased to conduct all activities with respect to the test kit;

    • (b) the test kit is a medical device and is no longer approved for sale in Canada under the Medical Devices Regulations;

    • (c) one of the circumstances referred to in subparagraph 7(1)(a)(i) or (ii) exists; or

    • (d) the Minister has reasonable grounds to believe that the test kit is being used for a purpose other than a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose and that the test kit poses a risk to public health or safety, including the risk of the targeted substance in the test kit being diverted to an illicit market or use.

  • Marginal note:Effect of cancellation

    (2) When the registration number of a test kit is cancelled, the number

    • (a) must not be displayed on the label of any test kit manufactured or assembled after the cancellation; and

    • (b) in the case of a cancellation under paragraph (1)(a), must remain on the label of any existing test kit until all of the test kits with that registration number are disposed of.

  • SOR/2019-170, s. 2

Marginal note:Application for new number

  •  (1) The following persons may, after a period of 90 days following the cancellation of the registration number of a test kit, obtain a new registration number by submitting to the Minister an application that is supported by proof that the circumstances that gave rise to the cancellation have been corrected:

    • (a) the manufacturer or assembler of the test kit; or

    • (b) if the test kit is manufactured or assembled in accordance with a custom order, the person for whom the test kit was manufactured or assembled.

  • Marginal note:New number

    (2) On completion of the review of the application, the Minister must issue a new registration number for the test kit unless a condition referred to in any of paragraphs 9(1)(b) to (d) applies.

  • SOR/2010-223, s. 4
  • SOR/2019-170, s. 2

Marginal note:Notice to Minister

 The holder of a registration number for a test kit must inform the Minister in writing, within 30 days after the occurrence, if they have

  • (a) ceased to conduct all activities authorized by section 4 with respect to the test kit;

  • (b) transferred the manufacturing or assembly of the test kit to another person;

  • (c) increased the quantity of targeted substance in the test kit;

  • (d) changed the brand name of the test kit;

  • (e) altered in any manner the adulterating or denaturing agent in the test kit or changed the quantity of either agent in it; or

  • (f) substituted the adulterating or denaturing agent with another one.

  • SOR/2019-170, s. 2

Licensed Dealers

Authorized Activities

Marginal note:General

  •  (1) A licensed dealer may produce, assemble, sell, provide, transport, send, deliver, import or export a targeted substance if they comply with these Regulations and the terms and conditions of their dealer’s licence and any permit issued under these Regulations.

  • Marginal note:Qualified person in charge present

    (2) A licensed dealer may conduct an activity in relation to a targeted substance at their site only if the qualified person in charge or an alternate qualified person in charge is present at the site.

  • Marginal note:Permit — import and export

    (3) A licensed dealer must obtain a permit in order to import or export a targeted substance.

  • Marginal note:Possession for export

    (4) A licensed dealer may possess a targeted substance for the purpose of exporting it if they have obtained it in accordance with these Regulations.

  • SOR/2019-170, s. 2

Dealer’s Licences

Preliminary Requirements

Marginal note:Eligible persons

 The following persons may apply for a dealer’s licence:

  • (a) an individual who ordinarily resides in Canada;

  • (b) a corporation that has its head office in Canada or operates a branch office in Canada; or

  • (c) the holder of a position that includes responsibility for targeted substances on behalf of the Government of Canada or of a government of a province, a police force, a hospital or a university in Canada.

  • SOR/2019-170, s. 2

Marginal note:Senior person in charge

 An applicant for a dealer’s licence must designate only one individual as the senior person in charge, who has overall responsibility for management of the activities with respect to targeted substances that are specified in the licence application. The applicant may designate themself if the applicant is an individual.

  • SOR/2019-170, s. 2

Marginal note:Qualified person in charge

  •  (1) An applicant for a dealer’s licence must designate only one individual as the qualified person in charge, who is responsible for supervising the activities with respect to targeted substances that are specified in the licence application and for ensuring that those activities comply with these Regulations. The applicant may designate themself if the applicant is an individual.

  • Marginal note:Alternate qualified person in charge

    (2) An applicant for a dealer’s licence may designate an individual as an alternate qualified person in charge, who is authorized to replace the qualified person in charge when that person is absent. The applicant may designate themself if the applicant is an individual.

  • Marginal note:Qualifications

    (3) Only an individual who meets the following requirements may be designated as a qualified person in charge or an alternate qualified person in charge:

    • (a) they work at the site specified in the dealer’s licence;

    • (b) they

      • (i) are entitled or, if applicable, registered and entitled by a provincial professional licensing authority or a professional association in Canada and entitled to practise a profession that is relevant to their duties, such as pharmacist, practitioner, pharmacy technician or laboratory technician,

      • (ii) hold a diploma, certificate or credential awarded by a post-secondary educational institution in Canada in a field or occupation that is relevant to their duties, such as pharmacy, medicine, dentistry, veterinary medicine, pharmacology, chemistry, biology, pharmacy technician, laboratory technician, pharmaceutical regulatory affairs or supply chain management or security, or

      • (iii) hold a diploma, certificate or credential that is awarded by a foreign educational institution in a field or occupation referred to in subparagraph (ii) and hold

        • (A) an equivalency assessment as defined in subsection 73(1) of the Immigration and Refugee Protection Regulations, or

        • (B) an equivalency assessment issued by an organization or institution that is responsible for issuing equivalency assessments and is recognized by a province;

    • (c) they have sufficient knowledge of and experience with the use and handling of the targeted substances specified in the dealer’s licence to properly carry out their duties; and

    • (d) they have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities specified in the dealer’s licence to properly carry out their duties.

  • Marginal note:Exception

    (4) An applicant for a dealer’s licence may designate an individual who does not meet any of the requirements of paragraph (3)(b) as a qualified person in charge or an alternate qualified person in charge if

    • (a) no other individual working at the site meets those requirements;

    • (b) those requirements are not necessary for the activities specified in the licence; and

    • (c) the individual has sufficient knowledge — acquired from a combination of education, training or work experience — to properly carry out their duties.

  • SOR/2019-170, s. 2

Marginal note:Ineligibility

 An individual is not eligible to be a senior person in charge, a qualified person in charge or an alternate qualified person in charge if, during the 10 years before the day on which the dealer’s licence application is submitted,

  • (a) in respect of a designated substance offence or a designated criminal offence or a designated offence as defined in subsection 2(1) of the Cannabis Act, the individual

    • (i) was convicted as an adult, or

    • (ii) was a young person who received an adult sentence, as those terms are defined in subsection 2(1) of the Youth Criminal Justice Act; or

  • (b) in respect of an offence committed outside Canada that, if committed in Canada, would have constituted a designated substance offence or a designated criminal offence or a designated offence as defined in subsection 2(1) of the Cannabis Act,

    • (i) the individual was convicted as an adult, or

    • (ii) if they committed the offence when they were at least 14 years old but less than 18 years old, the individual received a sentence that was longer than the maximum youth sentence, as that term is defined in subsection 2(1) of the Youth Criminal Justice Act, that could have been imposed under that Act for such an offence.

  • SOR/2014-260, s. 29(E)
  • SOR/2019-170, s. 2

Issuance of Licence

Marginal note:Application

  •  (1) A person who intends to conduct an activity referred to in section 12 must obtain a dealer’s licence for each site at which they intend to conduct activities by submitting an application to the Minister that contains the following information:

    • (a) if the licence is requested by

      • (i) an individual, the individual’s name,

      • (ii) a corporation, its corporate name and any other name registered with a province under which it intends to conduct the activities specified in its dealer’s licence or by which it intends to identify itself, and

      • (iii) the holder of a position described in paragraph 13(c), the applicant’s name and the title of the position;

    • (b) the municipal address, telephone number and, if applicable, the email address of the proposed site and, if different from the municipal address, its mailing address;

    • (c) the name, date of birth, telephone number and email address of the proposed senior person in charge;

    • (d) with respect to each of the proposed qualified person in charge and any proposed alternate qualified person in charge,

      • (i) their name, date of birth, telephone number and email address,

      • (ii) the title of their position at the site,

      • (iii) the name and title of the position of their immediate supervisor at the site,

      • (iv) if applicable, the profession they practise that is relevant to their duties, the name of the province that authorizes them to practise it and their authorization number, and

      • (v) their education, training and work experience that are relevant to their duties;

    • (e) the activities that are to be conducted and the targeted substances in respect of which each of the activities is to be conducted;

    • (f) if the licence is requested to manufacture or assemble a product or compound that contains a targeted substance, other than a test kit, a list that includes, for each product or compound,

      • (i) the brand name of the product or the name of the compound,

      • (ii) the drug identification number that is assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any,

      • (iii) the specified name of the targeted substance in the product or compound,

      • (iv) the strength per unit of the targeted substance in it, the number of units per package and the number of packages,

      • (v) if it is to be manufactured or assembled by or for another licensed dealer under a custom order, the name, municipal address and licence number of the other licensed dealer, and

      • (vi) if the applicant’s name appears on the label of the product or compound, a copy of the inner label, as defined in section A.01.010 of the Food and Drug Regulations;

    • (g) if the licence is requested in order to produce a targeted substance other than a product or compound that contains a targeted substance,

      • (i) the specified name of the targeted substance,

      • (ii) the quantity that the applicant expects to produce under their licence and the period during which that quantity would be produced, and

      • (iii) if it is to be produced for another licensed dealer under a custom order, the name, municipal address and licence number of the other licensed dealer;

    • (h) if the licence is requested for an activity that is not described in paragraph (f) or (g), the specified name of the targeted substance for which the activity is to be conducted and the purpose of the activity;

    • (i) a detailed description of the security measures in place at the site, determined in accordance with the Security Directive; and

    • (j) a detailed description of the method for recording information that the applicant proposes to use for the purpose of section 40.

  • Marginal note:Documents

    (2) An application for a dealer’s licence must be accompanied by the following documents:

    • (a) if the applicant is a corporation, a copy of

      • (i) the certificate of incorporation or other constituting instrument, and

      • (ii) any document filed with the province in which its site is located that states its corporate name and any other name registered with the province under which the applicant intends to conduct the activities specified in its dealer’s licence or by which it intends to identify itself;

    • (b) individual declarations signed and dated by each of the proposed senior person in charge, and qualified person in charge and any proposed alternate qualified person in charge, attesting that the person is not ineligible for a reason specified in section 16;

    • (c) a document issued by a Canadian police force in relation to each person referred to in paragraph (b), indicating whether, during the 10 years before the day on which the application is submitted, the person was convicted as specified in subparagraph 16(a)(i) or received a sentence as specified in subparagraph 16(a)(ii);

    • (d) if any of the persons referred to in paragraph (b) has ordinarily resided in a country other than Canada during the 10 years before the day on which the application is submitted, a document issued by a police force of that country indicating whether in that period that person was convicted as specified in subparagraph 16(b)(i) or received a sentence as specified in subparagraph 16(b)(ii);

    • (e) a declaration, signed and dated by the proposed senior person in charge, attesting that the proposed qualified person in charge and any proposed alternate qualified person in charge have the knowledge and experience required under paragraphs 15(3)(c) and (d); and

    • (f) if the proposed qualified person in charge or any proposed alternate qualified person in charge does not meet the requirement of subparagraph 15(3)(b)(i), either

      • (i) a copy of the person’s diploma, certificate or credential referred to in subparagraph 15(3)(b)(ii) or (iii), or

      • (ii) a detailed description of the education, training and work experience that is required under paragraph 15(4)(c), together with supporting evidence, such as a copy of a course transcript or an attestation by the person who provided the training.

  • Marginal note:Signature and attestation

    (3) The application must

    • (a) be signed and dated by the proposed senior person in charge; and

    • (b) include an attestation by that person that

      • (i) all of the information and documents submitted in support of the application are correct and complete to the best of their knowledge, and

      • (ii) they have the authority to bind the applicant.

  • Marginal note:Additional information and documents

    (4) The applicant must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2014-260, s. 30(E)
  • SOR/2019-170, s. 2

Marginal note:Issuance

 Subject to section 17.3, on completion of the review of the licence application, the Minister must issue a dealer’s licence, with or without terms and conditions, that contains

  • (a) the licence number;

  • (b) the name of the licensed dealer, their corporate name or the title of the position they hold;

  • (c) the activities that are authorized and the specified names of the targeted substances in respect of which each activity may be conducted;

  • (d) the municipal address of the site at which the dealer may conduct the authorized activities;

  • (e) the security level at the site, determined in accordance with the Security Directive;

  • (f) the effective date of the licence;

  • (g) the expiry date of the licence, which must be not later than three years after its effective date;

  • (h) any terms and conditions that the Minister has reasonable grounds to believe are necessary to

    • (i) ensure that an international obligation is respected,

    • (ii) ensure conformity with the requirements associated with the security level that is referred to in paragraph (e), or

    • (iii) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use; and

  • (i) if the licensed dealer produces a targeted substance, the quantity that they may produce and the authorized production period.

  • SOR/2019-170, s. 2

Marginal note:Validity

 A dealer’s licence is valid until the expiry date set out in the licence or, if it is earlier, the date of the suspension or revocation of the licence under section 23 or 24.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to issue a dealer’s licence if

    • (a) the applicant may not apply for a licence under section 13;

    • (b) during the 10 years before the day on which the licence application is submitted, the applicant has contravened

      • (i) a provision of the Act, the Cannabis Act or their regulations, or

      • (ii) a term or condition of a licence or permit issued to the applicant under any regulations made under the Act or issued to the applicant under the Cannabis Act or its regulations;

    • (c) during the 10 years before the day on which the application is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 16(a)(i) or (b)(i) or received a sentence as specified in subparagraph 16(a)(ii) or (b)(ii);

    • (d) an activity for which the licence is requested would contravene an international obligation;

    • (e) the applicant does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the licence is requested;

    • (f) the method referred to in paragraph 17(1)(j) does not permit the recording of information as required by section 40;

    • (g) the applicant has not complied with the requirements of subsection 17(4) or the information or documents that they have provided are not sufficient to complete the review of the licence application;

    • (h) the Minister has reasonable grounds to believe that the applicant has submitted false or misleading information or false or falsified documents in or in support of the licence application;

    • (i) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the applicant has been involved in the diversion of a targeted substance to an illicit market or use or has been involved in an activity that contravenes an international obligation; or

    • (j) the Minister has reasonable grounds to believe that the issuance of the licence would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Exceptions

    (2) The Minister must not refuse to issue a licence under paragraph (1)(b) or (h) if the applicant meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the applicant does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and

    • (b) the applicant has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.

  • Marginal note:Notice

    (3) Before refusing to issue a licence, the Minister must send the applicant a notice that sets out the Minister’s reasons and gives the applicant an opportunity to be heard.

  • SOR/2019-170, s. 2

Renewal of Licence

Marginal note:Application

  •  (1) To apply to renew a dealer’s licence, a licensed dealer must submit to the Minister an application that contains the information and documents referred to in subsections 17(1) and (2).

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the senior person in charge of the site specified in the application; and

    • (b) include an attestation by that person that

      • (i) all of the information and documents submitted in support of the application are correct and complete to the best of their knowledge, and

      • (ii) they have the authority to bind the licensed dealer.

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2019-170, s. 2

Marginal note:Renewal

  •  (1) Subject to section 18.3, on completion of the review of the renewal application, the Minister must issue a renewed dealer’s licence that contains the information specified in section 17.1.

  • Marginal note:Terms and conditions

    (2) When renewing a dealer’s licence, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to it or modify or delete one in order to

    • (a) ensure that an international obligation is respected;

    • (b) ensure conformity with the requirements associated with the security level specified in the licence or the new level required as a result of the licence renewal; or

    • (c) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Marginal note:Validity

 A renewed dealer’s licence is valid until the expiry date set out in the licence or, if it is earlier, the date of the suspension or revocation of the licence under section 23 or 24.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to renew a dealer’s licence if

    • (a) the licensed dealer may no longer apply for a licence under section 13;

    • (b) during the 10 years before the day on which the renewal application is submitted, the licensed dealer has contravened

      • (i) a provision of the Act, the Cannabis Act or their regulations, or

      • (ii) a term or condition of a licence or permit issued to the dealer under a regulation made under the Act or issued to the dealer under the Cannabis Act or its regulations;

    • (c) during the 10 years before the day on which the renewal application is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 16(a)(i) or (b)(i) or received a sentence as specified in subparagraph 16(a)(ii) or (b)(ii);

    • (d) an activity for which the renewal is requested would contravene an international obligation;

    • (e) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the renewal is requested;

    • (f) the method referred to in paragraph 17(1)(j) does not permit the recording of information as required by section 40;

    • (g) the licensed dealer has not complied with the requirements of subsection 18(3) or the information or documents that they have provided are not sufficient to complete the review of the renewal application;

    • (h) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the renewal application;

    • (i) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a targeted substance to an illicit market or use or has been involved in an activity that contravened an international obligation; or

    • (j) the Minister has reasonable grounds to believe that the renewal of the licence would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Exceptions

    (2) The Minister must not refuse to renew a licence under paragraph (1)(b) or (h) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the licensed dealer does not have a history of non-compliance with the Act or the Cannabis Act or their regulations; and

    • (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.

  • Marginal note:Notice

    (3) Before refusing to renew a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2019-170, s. 2

Amendment of Licence

Marginal note:Application

  •  (1) Before making a change affecting any information referred to in section 17.1 that is contained in their dealer’s licence, a licensed dealer must submit to the Minister an application to amend the licence that contains a description of the proposed amendment, as well as the information and documents referred to in section 17 that are relevant to the proposed amendment.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the senior person in charge of the site specified in the application; and

    • (b) include an attestation by that person that

      • (i) all of the information and documents submitted in support of the application are correct and complete to the best of their knowledge, and

      • (ii) they have the authority to bind the licensed dealer.

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2010-223, s. 5
  • SOR/2012-230, s. 26
  • SOR/2014-260, s. 39(F)
  • SOR/2019-170, s. 2

Marginal note:Amendment

  •  (1) Subject to section 19.3, on completion of the review of the amendment application, the Minister must amend the dealer’s licence.

  • Marginal note:Terms and conditions

    (2) When amending a dealer’s licence, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to it or modify or delete one in order to

    • (a) ensure that an international obligation is respected;

    • (b) ensure conformity with the requirements associated with the security level specified in the licence or the new level required as a result of the amendment; or

    • (c) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Marginal note:Validity

 An amended dealer’s licence is valid until the expiry date set out in the licence or, if it is earlier, the date of the suspension or revocation of the licence under section 23 or 24.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to amend a dealer’s licence if

    • (a) an activity for which the amendment is requested would contravene an international obligation;

    • (b) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of an activity for which the amendment is requested;

    • (c) the method referred to in paragraph 17(1)(j) does not permit the recording of information as required by section 40;

    • (d) the licensed dealer has not complied with the requirements of subsection 19(3) or the information or documents that they have provided are not sufficient to complete the review of the amendment application;

    • (e) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the amendment application; or

    • (f) the Minister has reasonable grounds to believe that the amendment of the licence would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Exceptions

    (2) The Minister must not refuse to amend a licence under paragraph (1)(e) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and

    • (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their Regulations.

  • Marginal note:Notice

    (3) Before refusing to amend a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2019-170, s. 2

Changes Requiring Prior Approval by Minister

Marginal note:Application

  •  (1) A licensed dealer must obtain the Minister’s approval before making any of the following changes by submitting a written application to the Minister:

    • (a) a change affecting the security measures in place at the site specified in the dealer’s licence;

    • (b) the replacement of the senior person in charge;

    • (c) the replacement of the qualified person in charge; or

    • (d) the replacement or addition of an alternate qualified person in charge.

  • Marginal note:Information and documents

    (2) The licensed dealer must provide the Minister with the following with respect to a change referred to in subsection (1):

    • (a) in the case of a change affecting the security measures in place at the site specified in the dealer’s licence, details of the change;

    • (b) in the case of the senior person in charge,

      • (i) the information specified in paragraph 17(1)(c), and

      • (ii) the declaration specified in paragraph 17(2)(b) and the documents specified in paragraphs 17(2)(c) and (d); and

    • (c) in the case of the qualified person in charge or an alternate qualified person in charge,

      • (i) the information specified in paragraph 17(1)(d), and

      • (ii) the declarations specified in paragraphs 17(2)(b) and (e) and the documents specified in paragraphs 17(2)(c), (d) and (f).

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2010-223, ss. 6, 42(E)
  • SOR/2012-230, s. 27
  • SOR/2014-260, ss. 31, 39(F)
  • SOR/2019-170, s. 2

Marginal note:Approval

  •  (1) Subject to section 20.2, on completion of the review of the application for approval of the change, the Minister must approve the change.

  • Marginal note:Terms and conditions

    (2) When approving a change, the Minister may, if he or she has reasonable grounds to believe that it is necessary to do so, add a term or condition to the licence or modify or delete one in order to

    • (a) ensure that an international obligation is respected;

    • (b) ensure conformity with the requirements associated with the security level specified in the licence; or

    • (c) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to approve the change if

    • (a) during the 10 years before the day on which the application for approval of the change is submitted, the proposed senior person in charge or qualified person in charge or any proposed alternate qualified person in charge was convicted as specified in subparagraph 16(a)(i) or (b)(i) or received a sentence as specified in subparagraph 16(a)(ii) or (b)(ii);

    • (b) the licensed dealer has not complied with the requirements of subsection 20(3) or the information or documents that they have provided are not sufficient to complete the review of the application for approval of the change;

    • (c) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the application for approval of the change; or

    • (d) the Minister has reasonable grounds to believe that the change would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Exceptions

    (2) The Minister must not refuse to approve a change under paragraph (1)(c) if the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use.

  • Marginal note:Notice

    (3) Before refusing to approve a change, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard in respect of them.

  • SOR/2019-170, s. 2

Changes Requiring Notice to Minister

Marginal note:Prior notice

  •  (1) A licensed dealer must notify the Minister in writing before

    • (a) manufacturing or assembling a product or compound that is not set out in the most recent version of the list referred to in paragraph 17(1)(f) that has been submitted to the Minister; or

    • (b) making a change to a product or compound that is set out in the list, if the change affects any of the information that has previously been submitted.

  • Marginal note:Information and list

    (2) The notice must contain the information referred to in paragraph 17(1)(f) that is necessary to update the list and must be accompanied by the revised version of the list.

  • SOR/2010-223, s. 43(F)
  • SOR/2014-260, s. 32
  • SOR/2019-170, s. 2

Marginal note:Notice — five days

 A licensed dealer must notify the Minister in writing within five days after a person ceases to act as the qualified person in charge or an alternate qualified person in charge.

  • SOR/2019-170, s. 2

Marginal note:Notice — 10 days

  •  (1) A licensed dealer must notify the Minister in writing within 10 days after one of the following changes occurs:

    • (a) a person ceases to act as the senior person in charge; or

    • (b) the licensed dealer ceases to manufacture or assemble a product or compound that is set out in the most recent version of the list referred to in paragraph 17(1)(f) that has been submitted to the Minister.

  • Marginal note:Information and list

    (2) A notice submitted under paragraph (1)(b) must specify which information referred to in paragraph 17(1)(f) is being changed and must be accompanied by the revised version of the list.

  • SOR/2019-170, s. 2

Marginal note:Notice of cessation of activities

  •  (1) A licensed dealer that intends to cease conducting activities at their site — whether on or before the expiry of their licence — must notify the Minister in writing to that effect at least 30 days before ceasing those activities.

  • Marginal note:Content of notice

    (2) The notice must be signed and dated by the senior person in charge and contain the following information:

    • (a) the expected date of the cessation of activities at the site;

    • (b) a description of the manner in which any remaining targeted substances on the site as of that date will be disposed of by the licensed dealer, including

      • (i) if some or all of them will be sold or provided to another licensed dealer that will be conducting activities at the same site, the name of that dealer,

      • (ii) if some or all of them will be sold or provided to another licensed dealer that will not be conducting activities at the same site, the name of that dealer and the municipal address of their site, and

      • (iii) if some or all of them will be destroyed, the date on which and the municipal address of the location at which the destruction is to take place;

    • (c) the municipal address of the location at which the licensed dealer’s documents will be kept after activities have ceased; and

    • (d) the name, municipal address, telephone number and, if applicable, the email address of a person who the Minister may contact for further information after activities have ceased.

  • Marginal note:Update

    (3) After having ceased to conduct the activities, the licensed dealer must submit to the Minister a detailed update of the information referred to in subsection (2) if it differs from what was set out in the notice. The update must be signed and dated by the senior person in charge.

  • SOR/2019-170, s. 2

Changes to Terms and Conditions of Licence

Marginal note:Addition of or modification to term or condition

  •  (1) The Minister may, at any time other than at the issuance, renewal or amendment of a dealer’s licence, add a term or condition to it or modify one if the Minister has reasonable grounds to believe that it is necessary to do so to

    • (a) ensure that an international obligation is respected;

    • (b) ensure conformity with the requirements associated with the security level specified in the licence; or

    • (c) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Notice

    (2) Before adding a term or condition to a licence or modifying one, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • Marginal note:Urgent circumstances

    (3) Despite subsection (2), the Minister may add a term or condition to a licence or modify one without prior notice if the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use.

  • Marginal note:Urgent circumstances — notice

    (4) The addition or modification of a term or condition that is made under subsection (3) takes effect as soon as the Minister sends the licensed dealer a notice that

    • (a) sets out the reasons for the addition or modification;

    • (b) gives the dealer an opportunity to be heard; and

    • (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.

  • SOR/2010-223, s. 7
  • SOR/2019-170, s. 2

Marginal note:Deletion of term or condition

  •  (1) The Minister may delete a term or condition of a dealer’s licence that the Minister determines is no longer necessary.

  • Marginal note:Notice

    (2) The deletion takes effect as soon as the Minister sends the licensed dealer a notice to that effect.

  • SOR/2019-170, s. 2

Suspension and Revocation of Licence

Marginal note:Suspension

  •  (1) The Minister must suspend a dealer’s licence without prior notice if the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use.

  • Marginal note:Notice

    (2) The suspension takes effect as soon as the Minister sends the licensed dealer a notice that

    • (a) sets out the reasons for the suspension;

    • (b) gives the dealer an opportunity to be heard; and

    • (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.

  • Marginal note:Reinstatement of licence

    (3) The Minister must reinstate the licence if the Minister has reasonable grounds to believe that the suspension is no longer necessary.

  • SOR/2019-170, s. 2

Marginal note:Revocation

  •  (1) Subject to subsection (2), the Minister must revoke a dealer’s licence if

    • (a) the licensed dealer may no longer apply for a licence under section 13;

    • (b) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the licence or the actual or potential unauthorized use of the licence;

    • (c) the licensed dealer ceases to conduct activities at their site before the expiry of their licence;

    • (d) the licensed dealer does not take the corrective measures specified in an undertaking or notice;

    • (e) the licensed dealer has contravened

      • (i) a provision of the Act, the Cannabis Act or their regulations, or

      • (ii) a term or condition of a licence or permit issued to the dealer under a regulation made under the Act or issued to the dealer under the Cannabis Act or its regulations;

    • (f) during the 10 years before the day on which the licence is revoked, the senior person in charge, the qualified person in charge or any alternate qualified person in charge was convicted as specified in subparagraph 16(a)(i) or (b)(i) or received a sentence as specified in subparagraph 16(a)(ii) or (b)(ii);

    • (g) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of an application relating to the licence; or

    • (h) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a targeted substance to an illicit market or use.

  • Marginal note:Exceptions

    (2) The Minister must not revoke a dealer’s licence for a ground set out in paragraph (1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and

    • (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.

  • Marginal note:Notice

    (3) Before revoking a licence, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2010-223, s. 42(E)
  • SOR/2019-170, s. 2

Marginal note:Return of licence

 The licensed dealer must return the original of the licence to the Minister within 15 days after the effective date of the revocation.

  • SOR/2019-170, s. 2

Import Permits

Marginal note:Application

  •  (1) A licensed dealer must submit to the Minister, before each importation of a targeted substance, an application for an import permit that contains the following information:

    • (a) their name, municipal address and dealer’s licence number;

    • (b) with respect to the targeted substance to be imported,

      • (i) its specified name, as set out in the dealer’s licence,

      • (ii) if it is a salt, the name of the salt,

      • (iii) its quantity, and

      • (iv) in the case of a raw material, its purity and its anhydrous content;

    • (c) if the targeted substance is contained in a product to be imported,

      • (i) the brand name of the product,

      • (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and

      • (iii) the strength per unit of the targeted substance in the product, the number of units per package and the number of packages;

    • (d) the name and municipal address, in the country of export, of the exporter from whom the targeted substance is being obtained;

    • (e) the name of the customs office where the importation is anticipated; and

    • (f) each proposed mode of transportation and any proposed country of transit or transhipment.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and

    • (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge.

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2010-223, ss. 8, 42(E), 43(F)
  • SOR/2019-170, s. 2

Marginal note:Issuance

 Subject to section 25.4, on completion of the review of the import permit application, the Minister must issue to the licensed dealer an import permit that contains

  • (a) the permit number;

  • (b) the information set out in subsection 25(1);

  • (c) the effective date of the permit;

  • (d) the expiry date of the permit, being the earlier of

    • (i) a date specified by the Minister that is not more than 180 days after its effective date, and

    • (ii) the expiry date of the dealer’s licence; and

  • (e) any terms and conditions that the Minister has reasonable grounds to believe are necessary to

    • (i) ensure that an international obligation is respected, or

    • (ii) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Marginal note:Validity

 An import permit is valid until the earliest of

  • (a) the expiry date set out in the permit,

  • (b) the date of the suspension or revocation of the permit under section 26 or 27,

  • (c) the date of the suspension or revocation of the dealer’s licence under section 23 or 24, and

  • (d) the date of the suspension or revocation of the export permit that applies to the targeted substance to be imported and that is issued by the competent authority in the country of export.

  • SOR/2019-170, s. 2

Marginal note:Return of permit

 If an import permit expires, the licensed dealer must return the original of the permit to the Minister within 15 days after its expiry.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to issue an import permit if

    • (a) the licensed dealer is not authorized by their dealer’s licence to import the relevant targeted substance or their licence will expire before the date of importation;

    • (b) the Minister has reasonable grounds to believe that the importation would contravene an international obligation;

    • (c) the licensed dealer does not have in place at the site the security measures set out in the Security Directive in respect of the importation;

    • (d) the licensed dealer has not complied with the requirements of subsection 25(3) or the information or documents that they have provided are not sufficient to complete the review of the permit application;

    • (e) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the permit application;

    • (f) the licensed dealer has been notified that their application to renew or amend their licence will be refused;

    • (g) the Minister has reasonable grounds to believe that the importation would contravene the laws of the country of export or any country of transit or transhipment; or

    • (h) the Minister has reasonable grounds to believe that the issuance of the permit would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Notice

    (2) Before refusing to issue the import permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2019-170, s. 2

Marginal note:Providing copy of permit

 The holder of an import permit must provide a copy of the permit to the customs office at the time of importation.

  • SOR/2019-170, s. 2

Marginal note:Declaration

 The holder of an import permit must provide the Minister, within 15 days after the day of release of the targeted substance specified in the permit in accordance with the Customs Act, with a declaration that contains the following information:

  • (a) their name and the numbers of their dealer’s licence and the import permit that applies to the targeted substance;

  • (b) with respect to the targeted substance,

    • (i) its specified name, as set out in the dealer’s licence,

    • (ii) if it is a salt, the name of the salt, and

    • (iii) its quantity;

  • (c) if the targeted substance is contained in a product that they have imported,

    • (i) the brand name of the product,

    • (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and

    • (iii) the strength per unit of the targeted substance in the product, the number of units per package and the number of packages; and

  • (d) the name of the customs office from which the targeted substance was released and the date of the release.

  • SOR/2019-170, s. 2

Marginal note:Suspension

  •  (1) The Minister must suspend an import permit without prior notice if

    • (a) the dealer’s licence is suspended;

    • (b) the Minister has reasonable grounds to believe that the suspension is necessary to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use; or

    • (c) the importation would contravene the laws of the country of export or any country of transit or transhipment.

  • Marginal note:Notice

    (2) The suspension takes effect as soon as the Minister sends the licensed dealer a notice that

    • (a) sets out the reasons for the suspension;

    • (b) gives the dealer an opportunity to be heard; and

    • (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.

  • Marginal note:Reinstatement of permit

    (3) The Minister must reinstate the import permit if the Minister has reasonable grounds to believe that the suspension is no longer necessary.

  • SOR/2010-223, s. 9(F)
  • SOR/2014-260, s. 39(F)
  • SOR/2019-170, s. 2

Marginal note:Revocation

  •  (1) Subject to subsection (2), the Minister must revoke an import permit if

    • (a) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the permit or the actual or potential unauthorized use of the permit;

    • (b) the licensed dealer does not carry out the corrective measures specified by the Minister under paragraph 26(2)(c) by the specified date;

    • (c) the licensed dealer has contravened a term or condition of the permit;

    • (d) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of the application for the permit;

    • (e) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a targeted substance to an illicit market or use; or

    • (f) the dealer’s licence has been revoked.

  • Marginal note:Exceptions

    (2) The Minister must not revoke an import permit for a ground set out in paragraph (1)(d) or 24(1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and

    • (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.

  • Marginal note:Notice

    (3) Before revoking an import permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2014-260, s. 40(F)
  • SOR/2019-170, s. 2

Marginal note:Return of permit

 If an import permit is revoked, the licensed dealer must return the original of the permit to the Minister within 15 days after the effective date of the revocation.

  • SOR/2019-170, s. 2

Export Permits

Marginal note:Application

  •  (1) A licensed dealer must submit to the Minister, before each exportation of a targeted substance, an application for an export permit that contains the following information and document:

    • (a) their name, municipal address and dealer’s licence number;

    • (b) with respect to the targeted substance to be exported,

      • (i) its specified name, as set out in the dealer’s licence,

      • (ii) if it is a salt, the name of the salt,

      • (iii) its quantity, and

      • (iv) in the case of a raw material, its purity and its anhydrous content;

    • (c) if the targeted substance is contained in a product to be exported,

      • (i) the brand name of the product,

      • (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and

      • (iii) the strength per unit of the targeted substance in the product, the number of units per package and the number of packages; and

    • (d) the name and municipal address of the importer in the country of final destination;

    • (e) the name of the customs office where the exportation is anticipated;

    • (f) each proposed mode of transportation and any proposed country of transit or transhipment; and

    • (g) a copy of the import permit issued by the competent authority in the country of final destination that sets out the name of the importer and the municipal address of their site in that country.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and

    • (b) include an attestation by that person that, to the best of their knowledge,

      • (i) the exportation does not contravene the laws of the country of final destination or any country of transit or transhipment, and

      • (ii) all of the information and documents submitted in support of the application are correct and complete.

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2010-223, s. 10
  • SOR/2014-260, ss. 39(F), 40(F)
  • SOR/2019-170, s. 2

Marginal note:Issuance

 Subject to section 28.4, on completion of the review of the export permit application, the Minister must issue to the licensed dealer an export permit that contains

  • (a) the permit number;

  • (b) the information set out in paragraphs 28(1)(a) to (f);

  • (c) the effective date of the permit;

  • (d) the expiry date of the permit, being the earliest of

    • (i) a date specified by the Minister that is not more than 180 days after its effective date,

    • (ii) the expiry date of the dealer’s licence, and

    • (iii) the expiry date of the import permit issued by the competent authority in the country of final destination; and

  • (e) any terms and conditions that the Minister has reasonable grounds to believe are necessary to

    • (i) ensure that an international obligation is respected, or

    • (ii) reduce a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Marginal note:Validity

 An export permit is valid until the earliest of

  • (a) the expiry date set out in the permit,

  • (b) the date of the suspension or revocation of the permit under section 29 or 30,

  • (c) the date of the suspension or revocation of the dealer’s licence under section 23 or 24, and

  • (d) the date of the expiry, suspension or revocation of the import permit that applies to the targeted substance to be exported and that is issued by the competent authority in the country of final destination.

  • SOR/2019-170, s. 2

Marginal note:Return of permit

 If an export permit expires, the licensed dealer must return the original of the permit to the Minister within 15 days after its expiry.

  • SOR/2019-170, s. 2

Marginal note:Refusal

  •  (1) The Minister must refuse to issue an export permit if

    • (a) the licensed dealer is not authorized by their dealer’s licence to export the relevant targeted substance or their dealer’s licence will expire before the date of export;

    • (b) the Minister has reasonable grounds to believe that the exportation would contravene an international obligation;

    • (c) the licensed dealer has not complied with the requirements of subsection 28(3) or the information or documents that they have provided are not sufficient to complete the review of the permit application;

    • (d) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the permit application;

    • (e) the licensed dealer has been notified that their application to renew or amend their licence will be refused;

    • (f) the Minister has reasonable grounds to believe that the exportation would not be in conformity with the import permit issued by the competent authority of the country of final destination;

    • (g) the Minister has reasonable grounds to believe that the exportation would contravene the laws of the country of final destination or any country of transit or transhipment; or

    • (h) the Minister has reasonable grounds to believe that the issuance of the permit would likely create a risk to public health or safety, including the risk of a targeted substance being diverted to an illicit market or use.

  • Marginal note:Notice

    (2) Before refusing to issue the export permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2019-170, s. 2

Marginal note:Providing copy of permit

 The holder of an export permit must provide a copy of the permit to the customs office at the time of exportation.

  • SOR/2019-170, s. 2

Marginal note:Declaration

 The holder of an export permit must provide the Minister, within 15 days after the day of export of the targeted substance specified in the permit, with a declaration that contains the following information:

  • (a) their name and the numbers of their dealer’s licence and the export permit that applies to the targeted substance;

  • (b) with respect to the targeted substance,

    • (i) its specified name, as set out in the dealer’s licence,

    • (ii) if it is a salt, the name of the salt, and

    • (iii) its quantity;

  • (c) if the targeted substance is contained in a product that they have exported,

    • (i) the brand name of the product,

    • (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any, and

    • (iii) the strength per unit of the targeted substance in the product, the number of units per package and the number of packages; and

  • (d) the name of the customs office from which the targeted substance was exported and the date of export.

  • SOR/2019-170, s. 2

Marginal note:Suspension

  •  (1) The Minister must suspend an export permit without prior notice if

    • (a) the dealer’s licence is suspended;

    • (b) the Minister has reasonable grounds to believe that the suspension is necessary to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use; or

    • (c) the exportation would contravene the laws of the country of final destination, or any country of transit or transhipment.

  • Marginal note:Notice

    (2) The suspension takes effect as soon as the Minister sends the licensed dealer a notice that

    • (a) sets out the reasons for the suspension;

    • (b) gives the dealer an opportunity to be heard; and

    • (c) if applicable, specifies the corrective measures that must be carried out and the date by which they must be carried out.

  • Marginal note:Reinstatement of permit

    (3) The Minister must reinstate the export permit if the Minister has reasonable grounds to believe that the suspension is no longer necessary.

  • SOR/2010-223, s. 11
  • SOR/2019-170, s. 2

Marginal note:Revocation

  •  (1) Subject to subsection (2), the Minister must revoke an export permit if

    • (a) the licensed dealer requests the Minister to do so or informs the Minister of the loss or theft of the permit or the actual or potential unauthorized use of the permit;

    • (b) the licensed dealer does not carry out the corrective measures specified by the Minister under paragraph 29(2)(c) by the specified date;

    • (c) the licensed dealer has contravened a term or condition of the permit;

    • (d) the Minister has reasonable grounds to believe that the licensed dealer submitted false or misleading information or false or falsified documents in or in support of the application for the permit;

    • (e) information received from a competent authority or the United Nations gives the Minister reasonable grounds to believe that the licensed dealer has been involved in the diversion of a targeted substance to an illicit market or use; or

    • (f) the dealer’s licence has been revoked.

  • Marginal note:Exceptions

    (2) The Minister must not revoke an export permit for a ground set out in paragraph (1)(d) or 24(1)(e) or (g) if the licensed dealer meets the following conditions, unless the Minister has reasonable grounds to believe that it is necessary to do so to protect public health or safety, including to prevent a targeted substance from being diverted to an illicit market or use:

    • (a) the licensed dealer does not have a history of non-compliance with the Act, the Cannabis Act or their regulations; and

    • (b) the licensed dealer has carried out, or signed an undertaking to carry out, the necessary corrective measures to ensure compliance with the Act, the Cannabis Act and their regulations.

  • Marginal note:Notice

    (3) Before revoking an export permit, the Minister must send the licensed dealer a notice that sets out the Minister’s reasons and gives the dealer an opportunity to be heard.

  • SOR/2010-223, s. 12(E)
  • SOR/2019-170, s. 2

Marginal note:Return of permit

 If an export permit is revoked, the licensed dealer must return the original of the permit to the Minister within 15 days after the effective date of the revocation.

  • SOR/2019-170, s. 2

Identification

Marginal note:Name

 A licensed dealer must include their name, as set out in their dealer’s licence, on all the means by which they identify themself in regard to their activities in relation to targeted substances, including labels, orders, shipping documents, invoices and advertising.

  • SOR/2010-223, s. 13
  • SOR/2019-170, s. 2

Sale of Targeted Substances

Marginal note:Specified persons

  •  (1) Subject to subsection (2), a licensed dealer may sell or provide a targeted substance to

    • (a) another licensed dealer;

    • (b) a pharmacist;

    • (c) a practitioner;

    • (d) a hospital;

    • (e) a person to whom an exemption relating to the substance has been granted under section 56 of the Act; or

    • (f) the Minister.

  • Marginal note:Exception — pharmacist or practitioner named in notice

    (2) The licensed dealer must not sell or provide a targeted substance to a pharmacist or practitioner named in a notice issued under section 79, unless the dealer has received a notice of retraction issued under section 80.

  • SOR/2019-170, s. 2

Marginal note:Order required

  •  (1) A licensed dealer may sell or provide a targeted substance in accordance with section 32 if the dealer has received from one of the following persons a written or verbal order indicating the specified name and the quantity of the substance and, in the case of a written order, the conditions specified in subsection (2) are met:

    • (a) in the case of a licensed dealer, a person who is authorized to place an order for the substance on their behalf;

    • (b) in the case of a hospital, the pharmacist in charge of the hospital’s pharmacy or a practitioner authorized by the person in charge of the hospital to sign the order; or

    • (c) in any other case, the person to whom the substance is to be sold or provided.

  • Marginal note:Conditions

    (2) The following conditions apply to a written order:

    • (a) it must be signed and dated by one of the persons referred to in subsection (1); and

    • (b) the licensed dealer must verify the signature if it is unknown to them.

  • SOR/2014-260, s. 39(F)
  • SOR/2019-170, s. 2

Marginal note:Anticipated multiple sales

  •  (1) A licensed dealer may sell or provide a targeted substance more than once in respect of one order if the order indicates

    • (a) the number of sales or provisions, not exceeding four;

    • (b) the specific quantity for each sale or provision; and

    • (c) the intervals between each sale and provision.

  • Marginal note:Multiple sales — insufficient stock

    (2) A licensed dealer may sell or provide a targeted substance more than once in respect of one order if, at the time of receipt of the order, the dealer temporarily does not have in stock the quantity of the substance ordered, in which case the dealer may sell or provide against the order the quantity of the substance that the dealer has available and deliver the balance later.

  • SOR/2019-170, s. 2

Packaging and Transportation

Marginal note:Packaging — sale and provision

  •  (1) A licensed dealer that sells or provides a targeted substance must securely package it in its immediate container, which must be sealed in such a manner that the container cannot be opened without breaking the seal.

  • Marginal note:Packaging — transport and export

    (2) A licensed dealer that transports or exports a targeted substance must ensure that its package is sealed in such a manner that the package cannot be opened without breaking the seal.

  • Marginal note:Exception

    (3) Subsection (1) does not apply to a test kit that contains a targeted substance and that has a registration number.

  • SOR/2010-223, ss. 14, 42(E)
  • SOR/2014-260, s. 39(F)
  • SOR/2019-170, s. 2

Marginal note:Transport

 A licensed dealer must, in taking delivery of a targeted substance that they have imported or in making delivery of a targeted substance,

  • (a) take any measures that are necessary to ensure the security of the targeted substance while it is being transported;

  • (b) in the case of an imported targeted substance, transport it directly to the site specified in their licence after it is released under the Customs Act; and

  • (c) in the case of a targeted substance that is to be exported, transport it directly from the site specified in their licence to the customs office where it will be exported.

  • SOR/2019-170, s. 2

Thefts, Losses and Suspicious Transactions

Marginal note:Protective measures

 A licensed dealer must take any measures that are necessary to ensure the security of any targeted substance in their possession and any licence or permit in their possession.

  • SOR/2010-223, s. 15(E)
  • SOR/2019-170, s. 2

Marginal note:Theft or loss — licences and permits

 A licensed dealer that becomes aware of a theft or loss of their licence or permit must provide a written report to the Minister within 72 hours after becoming aware of it.

  • SOR/2019-170, s. 2

Marginal note:Theft or unexplainable loss — targeted substances

 A licensed dealer that becomes aware of a theft of a targeted substance or of a loss of a targeted substance that cannot be explained on the basis of normally accepted business activities must

  • (a) provide a written report to a member of a police force within 24 hours after becoming aware of the theft or loss; and

  • (b) provide a written report to the Minister within 72 hours after becoming aware of the theft or loss and include a confirmation that the report required under paragraph (a) has been provided.

  • SOR/2019-170, s. 2

Marginal note:Suspicious transaction

  •  (1) A licensed dealer must provide a written report containing the following information to the Minister within 72 hours after becoming aware of a transaction occurring in the course of their activities that they have reasonable grounds to suspect may be related to the diversion of a targeted substance to an illicit market or use:

    • (a) their name, municipal address, telephone number and, if the licensed dealer is a corporation, the position held by the individual making the report;

    • (b) the name and municipal address of the other party to the transaction;

    • (c) details of the transaction, including its date and time, its type, the specified name and quantity of the targeted substance and, in the case of a product or compound, the quantity of every targeted substance that it contains;

    • (d) in the case of a product that contains the targeted substance, other than a test kit, the drug identification number that is assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any; and

    • (e) a detailed description of the reasons for those suspicions.

  • Marginal note:Good faith

    (2) No civil proceedings lie against a licensed dealer for having provided the report in good faith.

  • Marginal note:Non-disclosure

    (3) A licensed dealer must not disclose that they have provided the report or disclose details of it, with the intent to prejudice a criminal investigation, whether or not a criminal investigation has begun.

  • SOR/2019-170, s. 2

Marginal note:Partial protection against self-incrimination

 A report made under any of sections 35.1 to 35.3, or any evidence derived from it, is not to be used or received to incriminate the licensed dealer in any criminal proceeding against them other than a prosecution under section 132, 136 or 137 of the Criminal Code.

  • SOR/2019-170, s. 2

Destruction of Targeted Substances

Marginal note:Destruction at site

 A licensed dealer that intends to destroy a targeted substance at the site specified in their licence must ensure that the following conditions are met:

  • (a) the licensed dealer obtains the prior approval of the Minister;

  • (b) the destruction is carried out in the presence of two of the following persons, at least one of whom must be a person referred to in subparagraph (i):

    • (i) the senior person in charge, the qualified person in charge or an alternate qualified person in charge, and

    • (ii) a person who works for or provides services to the licensed dealer and holds a senior position;

  • (c) the destruction is carried out in accordance with a method that complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction; and

  • (d) as soon as the destruction is completed, the person who carried out the destruction and each of the two persons referred to in paragraph (b) who were present at the destruction sign and date a joint declaration attesting that the targeted substance was completely destroyed, to which each signatory must add their name in printed letters.

  • SOR/2010-223, ss. 16, 42(E)
  • SOR/2019-170, s. 2

Marginal note:Destruction elsewhere than at site

 A licensed dealer that intends to destroy a targeted substance elsewhere than at the site specified in their licence must ensure that the following conditions are met:

  • (a) the licensed dealer obtains the prior approval of the Minister to carry out the destruction;

  • (b) the licensed dealer takes any measures that are necessary to ensure the security of the targeted substance while it is being transported in order to prevent its diversion to an illicit market or use;

  • (c) the destruction is carried out by a person working for a business that specializes in the destruction of dangerous goods and in the presence of another person working for that business;

  • (d) the destruction is carried out in accordance with a method that complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction; and

  • (e) as soon as the destruction is completed, the person who carried out the destruction provides the licensed dealer with a dated declaration attesting that the targeted substance was completely destroyed and containing

    • (i) the municipal address of the place of destruction,

    • (ii) the specified name and quantity of the targeted substance and, if applicable, the brand name and quantity of the product containing it or the name and quantity of the compound containing it,

    • (iii) the method of destruction,

    • (iv) the date of destruction, and

    • (v) the names in printed letters and signatures of that person and the other person who was present at the destruction.

  • SOR/2010-223, ss. 17, 43(F)
  • SOR/2019-170, s. 2

Marginal note:Application for prior approval

  •  (1) A licensed dealer must submit to the Minister an application that contains the following information in order to obtain the Minister’s prior approval to destroy a targeted substance:

    • (a) their name, municipal address and dealer’s licence number;

    • (b) the proposed date of destruction;

    • (c) the municipal address of the place of destruction;

    • (d) a brief description of the method of destruction;

    • (e) if the destruction is to be carried out at the site specified in the dealer’s licence, the names of the persons proposed for the purpose of paragraph 36(b) and information establishing that they meet the conditions of that paragraph;

    • (f) the specified name of the targeted substance and, if applicable, the brand name of the product containing it or the name of the compound containing it; and

    • (g) the form and quantity of the targeted substance or the product or compound containing it and, if applicable, the strength per unit of the targeted substance in the product or compound, the number of units per package and the number of packages.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the qualified person in charge or an alternate qualified person in charge; and

    • (b) include an attestation by that person that

      • (i) the proposed method of destruction complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction, and

      • (ii) all of the information submitted in support of the application is correct and complete to the best of the signatory’s knowledge.

  • Marginal note:Additional information and documents

    (3) The licensed dealer must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2010-223, s. 18
  • SOR/2019-170, s. 2

Marginal note:Approval

 On completion of the review of the approval application, the Minister must approve the destruction of the targeted substance unless

  • (a) in the case of a destruction that is to be carried out at the site specified in the dealer’s licence, the persons proposed for the purpose of paragraph 36(b) do not meet the conditions of that paragraph;

  • (b) the Minister has reasonable grounds to believe that the targeted substance would not be destroyed;

  • (c) the Minister has reasonable grounds to believe that the licensed dealer has submitted false or misleading information or false or falsified documents in or in support of the approval application;

  • (d) the targeted substance or a portion of it is required for the purposes of a criminal or administrative investigation or a preliminary inquiry, trial or other proceeding under any Act or its regulations; or

  • (e) the Minister has reasonable grounds to believe that the approval would likely create a risk to public health or safety, including the risk of the targeted substance being diverted to an illicit market or use.

  • SOR/2019-170, s. 2

Documents

Marginal note:Method of recording information

 A licensed dealer must record any information that they are required to record under these Regulations using a method that permits an audit of it to be made at any time.

  • SOR/2019-170, s. 2

Marginal note:Information — general

 A licensed dealer must record the following information:

  • (a) the specified name, the form and the quantity of any targeted substance that the dealer orders, the name of the person who placed the order on the dealer’s behalf and the date of the order;

  • (b) the specified name, the form and the quantity of any targeted substance that the dealer receives, the name and municipal address of the person who sold or provided it and the date on which it was received;

  • (c) in the case of a targeted substance that the dealer sells or provides,

    • (i) the brand name of the product or the name of the compound containing the targeted substance and the specified name of the targeted substance,

    • (ii) the drug identification number that has been assigned to the product under section C.01.014.2 of the Food and Drug Regulations, if any,

    • (iii) the form and quantity of the targeted substance and, if applicable, the strength per unit of the targeted substance in the product or compound, the number of units per package and the number of packages,

    • (iv) the name and municipal address of the person to whom it was sold or provided, and

    • (v) the date on which it was sold or provided;

  • (d) the specified name, the form and the quantity of any targeted substance that the dealer produces and the date on which it was placed in stock and, if applicable, the strength per unit of the targeted substance in the product or compound, the number of units per package and the number of packages;

  • (e) the specified name and the quantity of any targeted substance that the dealer uses in the manufacturing or assembling of a product or compound, as well as the brand name and quantity of the product or the name and quantity of the compound, and the date on which the product or compound was placed in stock;

  • (f) the specified name, the form and the quantity of any targeted substance in stock at the end of each month;

  • (g) the specified name, the form and the quantity of any targeted substance that the dealer delivers, transports or sends, the name and municipal address of the consignee and the date on which it was delivered, transported or sent;

  • (h) the specified name, the form and the quantity of any targeted substance that the dealer imports, the date on which it was imported, the name and municipal address of the exporter, the country of exportation and any country of transit or transhipment; and

  • (i) the specified name, the form and the quantity of any targeted substance that the dealer exports, the date on which it was exported, the name and municipal address of the importer, the country of final destination and any country of transit or transhipment.

  • SOR/2010-223, s. 19
  • SOR/2019-170, s. 2

Marginal note:Verbal order

 A licensed dealer that receives a verbal order for a targeted substance must immediately record the following information:

  • (a) the name of the person who placed the order;

  • (b) the date on which the order was received; and

  • (c) the name of the person recording the order.

  • SOR/2010-223, ss. 20, 42(E)
  • SOR/2019-170, s. 2

Marginal note:Explainable loss of targeted substance

 A licensed dealer that becomes aware of a loss of a targeted substance that can be explained on the basis of normally accepted business activities must record the following information:

  • (a) the name of the lost targeted substance and, if applicable, the brand name of the product or the name of the compound containing it;

  • (b) the form and quantity of the targeted substance and, if applicable, the form of the product or compound containing it, the strength per unit of the targeted substance in the product or compound, the number of units per package and the number of packages;

  • (c) the date on which the dealer became aware of the loss; and

  • (d) the explanation for the loss.

  • SOR/2010-223, ss. 21, 43(F)
  • SOR/2019-170, s. 2

Marginal note:Destruction

 A licensed dealer must record the following information concerning any targeted substance that they destroy at the site specified in their licence:

  • (a) the municipal address of the place of destruction;

  • (b) the specified name, the form and the quantity of the targeted substance and, if applicable, the brand name and quantity of the product containing the targeted substance or the name and quantity of the compound containing the targeted substance;

  • (c) the method of destruction; and

  • (d) the date of destruction.

  • SOR/2010-223, s. 22
  • SOR/2019-170, s. 2

Marginal note:Annual report

  •  (1) Subject to subsections (2) and (3), a licensed dealer must provide to the Minister, within three months after the end of each calendar year, an annual report that contains

    • (a) the specified name, the form and the total quantity of each targeted substance that they receive, produce, assemble, sell, provide, import, export or destroy during the calendar year, as well as the name and total quantity of each targeted substance that they use to manufacture or assemble a product or compound;

    • (b) the specified name, the form and the quantity of each targeted substance in physical inventory taken at the site specified in their licence at the end of the calendar year; and

    • (c) the specified name, the form and the quantity of any targeted substance that has been lost or stolen in the course of conducting activities during the calendar year.

  • Marginal note:Non-renewal or revocation within first three months

    (2) If a licensed dealer’s licence expires without being renewed or is revoked during the first three months of a calendar year, the dealer must provide to the Minister

    • (a) within three months after the end of the preceding calendar year, the annual report in respect of that year; and

    • (b) within three months after the expiry or revocation, a report in respect of the portion of the current calendar year during which the licence was valid that contains the information referred to in subsection (1), in which the quantity in physical inventory is to be calculated as of the date of expiry or revocation.

  • Marginal note:Non-renewal or revocation after third month

    (3) If a licensed dealer’s licence expires without being renewed or is revoked after the first three months of a calendar year, the dealer must provide to the Minister, within three months after the expiry or revocation, a report in respect of the portion of the calendar year during which the licence was valid that contains the information referred to in subsection (1) for that period, in which the quantity in physical inventory is to be calculated as of the date of expiry or revocation.

  • SOR/2019-170, s. 2

 [Repealed, SOR/2019-170, s. 2]

 [Repealed, SOR/2019-170, s. 2]

Pharmacists

Permitted Activities

Marginal note:Application

 Sections 49 to 56 do not apply to a pharmacist when they are practising in a hospital.

  • SOR/2014-260, s. 34(F)
  • SOR/2019-170, s. 4

Marginal note:Authorization

 A pharmacist may, in accordance with sections 50 to 57, compound a targeted substance in accordance with a prescription.

  • SOR/2019-170, s. 4

Marginal note:Record of receipt from licensed dealer

 If a pharmacist receives a targeted substance from a licensed dealer, a pharmacist in another pharmacy or a hospital, the pharmacist must keep a record of the following information:

  • (a) the brand name of the targeted substance received or, if the targeted substance does not have a brand name, the specified name;

  • (b) the quantity and strength per unit of the targeted substance received, the number of units per package and the number of packages;

  • (c) the name and address of the licensed dealer, pharmacist or hospital that supplied it; and

  • (d) the date on which it was received.

  • SOR/2014-260, s. 39(F)

Marginal note:Prescription required

  •  (1) In addition to the activities authorized under section 55, a pharmacist may, subject to section 52, sell, provide, send, deliver or transport a targeted substance to or for an individual or for the benefit of an animal if

    • (a) the pharmacist sells or provides the substance in a container labelled in accordance with subsection (2);

    • (b) the transaction is made pursuant to a prescription

      • (i) dated and signed by a practitioner,

      • (ii) provided verbally to the pharmacist by a practitioner, or

      • (iii) transferred to the pharmacist under subsection 54(1) in accordance with subsection 54(2);

    • (c) the pharmacist has not transferred the prescription to another pharmacist; and

    • (d) when the prescription has been provided verbally, the transaction is recorded by the pharmacist in accordance with subsection (3).

  • Marginal note:Labelling required

    (2) A pharmacist who sells or provides a targeted substance to an individual must do so in a container that is labelled with the following information:

    • (a) the name and address of the pharmacy or pharmacist;

    • (b) the date of issuance of the prescription and the number given to it by the pharmacist;

    • (c) the name of the individual for whose benefit the targeted substance is sold or provided or, if it is sold or provided for the benefit of an animal, the name of the individual having caring of the animal or the name of the animal;

    • (d) the name of the practitioner who issued the prescription;

    • (e) the specified name or brand name of the targeted substance;

    • (f) the quantity and, if applicable, the strength per unit of the targeted substance; and

    • (g) the directions for use specified by the practitioner.

  • Marginal note:Record of verbal prescription

    (3) A pharmacist who receives a verbal prescription for a targeted substance must, before filling it,

    • (a) record the following information:

      • (i) the name and address of the individual for whose benefit the prescription is provided or, if it is provided for the benefit of an animal, the name and address of the individual having caring of the animal and, if applicable, the name of the animal,

      • (ii) the date that the verbal prescription was provided,

      • (iii) the specified name or brand name of the targeted substance, as specified in the prescription,

      • (iv) the quantity and, if applicable, the strength per unit of the targeted substance,

      • (v) the name of the recording pharmacist and the name of the practitioner who issued the prescription,

      • (vi) the directions for use specified by the practitioner, and

      • (vii) if the prescription is to be refilled, the number of times it may be refilled and, if specified, the interval between refills; and

    • (b) keep a hard copy or create a written record of the prescription.

  • SOR/2010-223, s. 24
  • SOR/2019-170, s. 5

Marginal note:Refills

 A pharmacist may only refill a prescription for a targeted substance if

  • (a) the practitioner who prescribed it expressly directs that the prescription may be refilled and specifies the number of refills;

  • (b) the pharmacist makes a record of each refill in accordance with section 53;

  • (c) less than one year has elapsed since the day on which the prescription was issued by the practitioner;

  • (d) at least one refill remains on the prescription; and

  • (e) in the case where an interval between refills has been specified by the practitioner, it has expired.

Marginal note:Records

 A pharmacist who fills or refills a prescription for a targeted substance must record the following information:

  • (a) the date the prescription was filled or refilled;

  • (b) the quantity of the targeted substance provided at the original filling and at each refill;

  • (c) the pharmacist’s name or initials; and

  • (d) the number assigned to the prescription.

Marginal note:Transfer of prescription

  •  (1) A pharmacist may transfer a prescription for a targeted substance to another pharmacist, except a prescription that has already been transferred.

  • Marginal note:Additional information

    (2) Before a pharmacist sells or provides a targeted substance to an individual under a prescription transferred under subsection (1), the pharmacist must

    • (a) in the case of a verbal transfer, record the information required by subsection 51(3);

    • (b) in the case of a written transfer, have obtained from the transferring pharmacist a copy of

      • (i) the prescription written by the practitioner, or

      • (ii) the record made in accordance with subsection 51(3) of the practitioner’s verbal prescription; and

    • (c) in all cases, record

      • (i) the name and address of the transferring pharmacist,

      • (ii) the number of authorized refills remaining and, if applicable, the specified interval between refills, and

      • (iii) the date of the last refill.

  • Marginal note:Records — transferring pharmacist

    (3) A pharmacist who transfers a prescription under subsection (1) must record the date of the transfer, the name of the pharmacist to whom the prescription was transferred, the name and address of the pharmacy where that pharmacist practises and, if applicable, the number of refills that are being transferred.

  • SOR/2014-260, s. 35(F)

Marginal note:Activities without a prescription

  •  (1) A pharmacist may sell, provide, send, deliver or transport a targeted substance without a prescription to any of the following persons on receipt of an order from that person that specifies the name and quantity of the targeted substance:

    • (a) if the order is written, a licensed dealer who

      • (i) sold or provided the targeted substance, or

      • (ii) is licensed to destroy targeted substances, other than those that the licensed dealer produced, made, assembled, sold or provided;

    • (b) subject to subsection (2),

      • (i) a practitioner,

      • (ii) another pharmacist, if the other pharmacist states that the targeted substance is required because of a delay or shortfall in an order for the targeted substance placed with a licensed dealer, or

      • (iii) a hospital, if the order is placed by a pharmacist practising in the hospital or by a practitioner who is authorized to order the targeted substance on behalf of the hospital;

    • (c) the Minister, if the order is a written order signed on the Minister’s behalf; or

    • (d) a person to whom an exemption with respect to the targeted substance has been granted under section 56 of the Act, if the order is a written order and is accompanied by a copy of the exemption.

  • Marginal note:Verbal orders

    (2) In the circumstances set out in subparagraphs (1)(b)(i) to (iii), if the order is verbal, the pharmacist must record the following information:

    • (a) the name and address of the pharmacist or practitioner placing the order;

    • (b) if the order was placed on behalf of an establishment, the name and address of the establishment;

    • (c) the date of the order;

    • (d) the specified name or the brand name of the targeted substance ordered, as specified in the order;

    • (e) the quantity and, if applicable, the strength per unit of the targeted substance; and

    • (f) the name of the recording pharmacist.

  • Marginal note:Records

    (3) A pharmacist who sells, provides, sends, delivers or transports a targeted substance without a prescription must keep a record of the following information:

    • (a) the brand name of the targeted substance or, if the targeted substance does not have a brand name, the specified name;

    • (b) the quantity and strength per unit of the targeted substance;

    • (c) the name and address of the person referred to in subsection (1) to whom the targeted substance was sold, provided, sent, delivered or transported; and

    • (d) the date of the transaction.

  • Marginal note:Copies

    (4) The pharmacist must keep the written order or, if the order is verbal, must create a hard copy of the order.

  • SOR/2010-223, s. 25
  • SOR/2019-170, s. 6(F)

General Obligations of Pharmacists

Marginal note:Change of location

 A pharmacist who closes premises in which a targeted substance has been stored must, not later than 10 days after the closure, inform the Minister of the date of closure, the location to which the targeted substance was moved and the quantity of the targeted substance that was moved.

Marginal note:Renunciation of privileges

  •  (1) A pharmacist who does not wish to receive or have possession of targeted substances may make a written request to the Minister to send to licensed dealers and pharmacies a notice, issued under section 79, that states that targeted substances must not be supplied to that pharmacist.

  • Marginal note:Prohibited actions

    (2) A pharmacist must not, unless their pharmacy has received a retraction issued under section 80,

    • (a) sell or provide a targeted substance to a pharmacist or practitioner named in a notice issued under section 79; or

    • (b) fill a prescription or order for a targeted substance from a practitioner named in a notice issued under section 79.

Practitioners

Marginal note:To patients only

 A practitioner may, with respect to a targeted substance, prescribe it for or administer it to an individual or animal, or sell, provide, send, deliver or transport it to or for an individual or for the benefit of an animal, only if

  • (a) the individual or animal is a patient that the practitioner is treating in their professional capacity; and

  • (b) the targeted substance is required to treat the individual’s or animal’s medical condition.

  • SOR/2010-223, s. 26(F)

Marginal note:Emergency supply

  •  (1) A practitioner of medicine may store an emergency supply of targeted substances at a remote location where emergency medical treatment is not readily available or in an emergency medical service vehicle, if the practitioner has an agent or mandatary at that location or in the vehicle who will control and administer the targeted substances on behalf of, and under the direction of, the practitioner.

  • Marginal note:Emergency use

    (2) When aid is being provided to an individual in an emergency, the agent or mandatary of the practitioner of medicine may administer a targeted substance from the emergency supply to the individual if

    • (a) the practitioner of medicine has, by telephone or other means, directed the agent or mandatary to administer the targeted substance; or

    • (b) the agent or mandatary follows written directives provided by the practitioner with respect to the administration of the targeted substance.

  • SOR/2010-223, s. 27
  • SOR/2018-69, s. 78(E)
  • SOR/2019-170, s. 8(F)

Marginal note:Records — practitioner

  •  (1) A practitioner must keep the following records:

    • (a) the brand name or, if the targeted substance does not have a brand name, the specified name, the quantity and strength per unit of any targeted substance received from a licensed dealer, pharmacist or hospital and the date on which it is received;

    • (b) the name and address of the licensed dealer, pharmacist or hospital that sold or provided the targeted substance;

    • (c) if a transaction involves a quantity of targeted substance that exceeds five times the usual daily dose for the substance, the name and quantity of the substance prescribed, administered, sold, provided, sent, delivered or transported, the name and address of the recipient and the date of the transaction; and

    • (d) in the case of an emergency supply referred to in subsection 59(1), the name of the administering agent or mandatary, the location of the emergency supply, the name, quantity and strength per unit of each targeted substance, the date of all transactions related to that emergency supply and the name of any individual to whom the targeted substance was administered.

  • Marginal note:Records — agent or mandatary

    (2) In respect of the administration of a targeted substance from an emergency supply referred to in subsection 59(1), the agent or mandatary of the practitioner must keep the following records:

    • (a) the name, strength per unit and quantity of each targeted substance administered and the date on which it was administered;

    • (b) the name of the individual to whom the targeted substance was administered; and

    • (c) the name of the agent or mandatary of the practitioner who administered the targeted substance.

  • SOR/2010-223, s. 28
  • SOR/2018-69, s. 78(E)

Marginal note:Obligations — agents

  •  (1) An agent or mandatary of a practitioner of medicine referred to in subsection 59(1) must

    • (a) take reasonable steps to protect any targeted substance in their possession from loss and theft; and

    • (b) inform the practitioner without delay of any loss or theft of a targeted substance.

  • Marginal note:Obligations — practitioner of medicine

    (2) A practitioner of medicine who is informed by their agent or mandatary of the loss or theft of a targeted substance must inform the Minister in accordance with subsection 72(2).

  • SOR/2018-69, s. 78(E)
  • SOR/2019-170, s. 9

Marginal note:Request for renunciation

 A practitioner who does not wish to receive or have possession of targeted substances may make a written request to the Minister to send to licensed dealers and pharmacies a notice issued under section 79 that states that

  • (a) recipients of the notice must not sell or provide any targeted substance to that practitioner; and

  • (b) pharmacists practising in the notified pharmacies must not fill a prescription or order for any targeted substance provided by that practitioner.

  • SOR/2010-223, s. 29(E)
  • SOR/2014-260, s. 36(F)

Hospitals

Marginal note:Authorization

  •  (1) A hospital may, in accordance with subsection (2) and sections 64 to 67, sell, provide, administer, send, deliver or transport a targeted substance.

  • Marginal note:Ordering targeted substances

    (2) No person may order a targeted substance on behalf of a hospital other than a pharmacist or practitioner practising in the hospital who is authorized by the person in charge of the hospital to order targeted substances for the hospital.

  • SOR/2019-170, s. 11

Marginal note:Provision or administration to a patient

 The person in charge of a hospital must not permit a targeted substance to be sold, provided or administered to a patient or animal under treatment as an in-patient or an out-patient of the hospital except pursuant to a prescription or other authorization of a practitioner practising in the hospital.

  • SOR/2014-260, s. 37(F)

Marginal note:Supply to non-patients

  •  (1) A pharmacist practising in a hospital or an individual who is authorized by the person in charge of a hospital to fill orders for targeted substances on behalf of the hospital may, on receipt of an order specifying the name, quantity and, if applicable, strength per unit of a targeted substance from any of the following persons, sell or provide the targeted substance to that person without a prescription:

    • (a) subject to subsection (2),

      • (i) a licensed dealer who

        • (A) sold or provided the substance, or

        • (B) is licensed to destroy targeted substances other than those that the licensed dealer produced, made, assembled, sold or provided,

      • (ii) a practitioner, if the practitioner states that the substance is required because of a delay or shortfall in an order for the substance placed with a licensed dealer or pharmacist,

      • (iii) a pharmacist, if the pharmacist states that the substance is required because of a delay or shortfall in an order for the substance placed with a licensed dealer, or

      • (iv) another hospital, if the order is placed by a pharmacist practising in the other hospital or a practitioner who is authorized to order the targeted substance on behalf of the other hospital and the order states that the substance is required because of a delay or shortfall in an order placed with a licensed dealer or a pharmacist;

    • (b) the Minister, if the order is a written order signed on the Minister’s behalf; and

    • (c) a person to whom an exemption with respect to the targeted substance has been granted under section 56 of the Act, if

      • (i) the person is an employee of or associated with the hospital, and

      • (ii) the order is a written order accompanied by a copy of the exemption.

  • Marginal note:Verbal orders

    (2) In the circumstances set out in paragraph (1)(a), if the order is verbal, the pharmacist practising in the hospital or the individual who is authorized by the person in charge of the hospital to fill orders for the targeted substance on behalf of the hospital must, before filling the order, record the following information:

    • (a) the date on which the order was received;

    • (b) the name and address of the person placing the order;

    • (c) the brand name of the targeted substance or, if the targeted substance does not have a brand name, the specified name;

    • (d) the quantity of the targeted substance ordered; and

    • (e) their name.

  • SOR/2019-170, s. 12(F)

Marginal note:Information

 The person in charge of a hospital must record, or cause to be recorded, the following information:

  • (a) the brand name or, if the targeted substance does not have a brand name, the specified name, the quantity of any targeted substance received by the hospital and the date on which it was received;

  • (b) the name and address of the licensed dealer, pharmacist or other hospital that sold or provided the targeted substance;

  • (c) the name and quantity of the targeted substance sold, provided, administered, sent, delivered or transported, the name and address of the recipient and the date of the transaction; and

  • (d) the name and address of any out-patient to whom a targeted substance is sold or provided under section 64.

  • SOR/2010-223, s. 30

Marginal note:Closure

 If a targeted substance is stored in a hospital or the pharmacy department of a hospital and the hospital or department closes, the person in charge of the hospital must, not later than 10 days after the day of the closure, inform the Minister of the date of closure, the location to which the targeted substance was moved and the quantity of the targeted substance that was moved.

  • SOR/2010-223, s. 31(E)

Individuals

Marginal note:Importation — Canadian residents

  •  (1) An individual who is a resident of Canada may, at the time of the individual’s return to Canada from a foreign country, import a targeted substance that is in their possession at the time of entry if

    • (a) the substance has been obtained under a prescription and is labelled with the information set out in paragraphs 51(2)(a) to (g);

    • (b) the individual is importing the substance

      • (i) for their own use,

      • (ii) for the use of a person for whom the individual is responsible and who is travelling with them, or

      • (iii) for the use of an animal for which the individual is responsible and that is travelling with them;

    • (c) the substance is imported to meet the medical needs of the individual or animal for whose benefit it is prescribed;

    • (d) the substance is declared to a customs office at the port of entry into Canada at the time of import; and

    • (e) the quantity being imported does not exceed the lesser of

      • (i) a single course of treatment, and

      • (ii) a 90-day supply, based on the usual daily dose.

  • Marginal note:Importation — foreign residents

    (2) An individual who is a resident of a foreign country may, at the time that the individual enters Canada, import a targeted substance that is in their possession at the time of entry if

    • (a) the requirements set out in paragraphs (1)(a) to (d) are met; and

    • (b) the quantity imported is the least of

      • (i) the content of the container,

      • (ii) a 90-day supply, based on the usual daily dose, and

      • (iii) the usual daily dose multiplied by the number of days that the individual will stay in Canada.

  • SOR/2019-170, s. 14

Marginal note:Export

 An individual may, at the time of their departure from Canada, export a targeted substance that is in their possession at the time of departure if

  • (a) the substance has been obtained under a prescription and is labelled with the information set out in paragraphs 51(2)(a) to (g);

  • (b) the individual is exporting the substance

    • (i) for their own use,

    • (ii) for the use of a person for whom the individual is responsible and who is travelling with them, or

    • (iii) for the use of an animal for which the individual is responsible and that is travelling with them;

  • (c) the substance is required to meet the medical needs of the individual or animal for whose benefit it is prescribed; and

  • (d) the quantity exported does not exceed the lesser of

    • (i) a single course of treatment, and

    • (ii) a 90-day supply, based on the usual daily dose.

  • SOR/2019-170, s. 15

Verification of Identity

Marginal note:Order

 Every person who fills an order or prescription for a targeted substance must verify the identity of the person who gave the order or issued the prescription if

  • (a) the signature on the order or prescription is unknown to the person; or

  • (b) the order or prescription is verbal and the person placing it is not known to the person.

  • SOR/2010-223, s. 32
  • SOR/2019-170, s. 16

Storage

Marginal note:Place

 Subject to section 59, every person who is authorized under these Regulations to deal in a targeted substance and who stores the targeted substance must do so in the place used for the purpose of conducting their business or professional practice and in the area in that place where only authorized employees have access, except if the targeted substance is for their own use or the use of another person for whom, or an animal for which, they are responsible.

  • SOR/2010-223, ss. 33, 42(E)
  • SOR/2019-170, s. 16

Security

Marginal note:Protective measures

  •  (1) The following persons must take any measures that are necessary to ensure the security of any targeted substance in their possession:

    • (a) a pharmacist;

    • (b) a practitioner;

    • (c) the person in charge of a hospital;

    • (d) a person to whom an exemption has been granted under section 56 of the Act; and

    • (e) a person who, in accordance with a permit for transit or transhipment, is responsible for the targeted substance while it is in transit or in transhipment in Canada.

  • Marginal note:Theft or loss

    (2) A person referred to in subsection (1) who becomes aware of a theft or loss of a targeted substance must provide a written report to the Minister within 10 days after becoming aware of the occurrence.

  • SOR/2010-223, ss. 34, 43(F)
  • SOR/2019-170, s. 16

Destruction

Marginal note:Restriction

  •  (1) Subject to subsection (2) and sections 36 and 37, a person must not destroy a targeted substance unless they have received it in accordance with these Regulations for their own use or the use of another person for whom, or an animal for which, they are responsible.

  • Marginal note:Conditions

    (2) A pharmacist, a practitioner or the person in charge of a hospital may destroy a targeted substance if

    • (a) subject to subsection (3), the destruction is witnessed by a pharmacist or practitioner;

    • (b) the targeted substance is destroyed using a method that complies with all federal, provincial and municipal environmental protection legislation applicable to the place of destruction;

    • (c) they record the following information:

      • (i) the municipal address of the place of destruction,

      • (ii) the specified name of the targeted substance to be destroyed and, if applicable, the brand name of the product containing it or the name of the compound containing it,

      • (iii) the form and quantity of the targeted substance to be destroyed or the product or compound containing it and, if applicable, its strength per unit, the number of units per package and the number of packages,

      • (iv) the method of destruction, and

      • (v) the date of the destruction; and

    • (d) immediately following the destruction, the person who carried out the destruction and the pharmacist or practitioner who witnessed it sign and date a joint declaration attesting that the targeted substance was completely destroyed, to which each signatory must add their name in printed letters.

  • Marginal note:Exception — open ampule

    (3) A targeted substance that constitutes the remainder of an open ampule, the partial contents of which have been administered to a patient, may be destroyed by a hospital employee who is a licensed health professional without a witness.

  • SOR/2010-223, s. 35(E)
  • SOR/2019-170, s. 16

Documents

Marginal note:Alteration prohibited

 A person must not make any mark on or alter or deface in any manner any licence, permit or registration number issued under these Regulations.

  • SOR/2010-223, s. 36
  • SOR/2019-170, s. 16

Marginal note:Retention period

 A person must keep any document containing all of the information that they are required to record under these Regulations, including every declaration and a copy of every report, for a period of two years following the day on which the last record is recorded in the document and in a manner that permits an audit of the document to be made at any time.

  • SOR/2019-170, s. 16

Marginal note:Location

 The documents must be kept

  • (a) in the case of a licensed dealer, at the site specified in their licence; and

  • (b) in the case of a former licensed dealer or any other person, at a location in Canada.

  • SOR/2019-170, s. 16

Marginal note:Quality of documents

 The documents must be complete and readily retrievable and the information in them must be legible and indelible.

  • SOR/2010-223, ss. 37(E), 42(E)
  • SOR/2018-69, s. 78(E)
  • SOR/2019-170, s. 16

Advertising

Marginal note:Restrictions

 It is prohibited to

  • (a) advertise a targeted substance to the general public; or

  • (b) publish any written advertisement respecting a targeted substance unless the advertisement

    • (i) is published in literature distributed to, or in a trade publication for, licensed dealers, pharmacists, practitioners or hospitals, and

    • (ii) displays the following symbol in a clear and conspicuous colour and size in the upper left quarter of its first page:

      The symbol consists of a square outline divided in half from top left corner to bottom right corner. An uppercase letter C appears in the centre of the top right half and an uppercase letter T appears in the centre of the lower left half.
  • SOR/2010-223, ss. 38(E), 43(F)
  • SOR/2019-170, s. 16

Minister

Marginal note:Notice of prohibition of sale

  •  (1) In the circumstances described in subsection (2), the Minister must send a notice to the persons and authorities specified in subsection (3) advising them that

    • (a) pharmacists practising in the notified pharmacies and all licensed dealers must not sell or provide any targeted substance to the pharmacist or the practitioner named in the notice;

    • (b) pharmacists practising in the notified pharmacies must not fill an order or prescription for any targeted substance provided by the practitioner named in the notice; or

    • (c) the prohibitions in both paragraphs (a) and (b) apply with respect to the practitioner named in the notice.

  • Marginal note:Circumstances requiring a notice

    (2) The notice must be sent if the pharmacist or practitioner named in the notice has

    • (a) made a request to the Minister in accordance with subsection 57(1) or section 62 to send the notice;

    • (b) contravened a rule of conduct established by the provincial professional licensing authority in the province in which the pharmacist or practitioner is practising and the authority has requested the Minister in writing to send the notice; or

    • (c) been convicted of a designated substance offence or of a contravention of these Regulations.

  • Marginal note:Recipients

    (3) The notice must be sent to

    • (a) all licensed dealers;

    • (b) all pharmacies within the province in which the pharmacist or practitioner named in the notice is registered and entitled to practise and is practising;

    • (c) the provincial professional licensing authority of the province in which the pharmacist or practitioner named in the notice is registered and entitled to practise;

    • (d) all pharmacies in an adjacent province in which a prescription or order from the pharmacist or practitioner named in the notice may be filled; and

    • (e) any provincial professional licensing authority in another province that has requested the Minister in writing to send the notice.

  • Marginal note:Other circumstances

    (4) The Minister may send the notice described in subsection (1) to the persons and authorities specified in subsection (3) if the Minister has taken the measures specified in subsection (5) and has reasonable grounds to believe that the pharmacist or practitioner named in the notice

    • (a) has contravened a provision of the Act or these Regulations;

    • (b) has, on more than one occasion, self-administered a targeted substance under a self-directed prescription or order or, in the absence of a prescription or order, contrary to accepted professional practice;

    • (c) has, on more than one occasion, prescribed, administered or provided a targeted substance to a person who is a spouse, common-law partner, parent or child of the pharmacist or practitioner, including a child adopted in fact, contrary to accepted professional practice; or

    • (d) is unable to account for a quantity of targeted substance for which the pharmacist or practitioner was responsible under these Regulations.

  • Marginal note:Measures before sending notice

    (5) The measures that must be taken before sending the notice are that the Minister has

    • (a) consulted with the provincial professional licensing authority of the province in which the pharmacist or practitioner to whom the notice relates is registered and entitled to practise;

    • (b) given that pharmacist or practitioner an opportunity to be heard; and

    • (c) considered

      • (i) the compliance history of the pharmacist or practitioner in respect of the Act and its regulations, and

      • (ii) whether the actions of the pharmacist or practitioner pose a risk to public health or safety, including the risk of the targeted substance being diverted to an illicit market or use.

  • SOR/2010-223, ss. 39, 43(F)
  • SOR/2014-260, s. 38
  • SOR/2019-170, s. 16

Marginal note:Prohibition of sale — notice of retraction

 The Minister must provide the persons and authorities who were sent a notice under subsection 79(1) with a notice of retraction of that notice if

  • (a) in the circumstance described in paragraph 79(2)(a), the requirements set out in subparagraphs (b)(i) and (ii) have been met and one year has elapsed since the notice was sent by the Minister; or

  • (b) in the circumstance described in any of paragraphs 79(2)(b) and (c) and (4)(a) to (d), the pharmacist or the practitioner named in the notice has

    • (i) requested in writing that a retraction of the notice be sent, and

    • (ii) provided a letter from the provincial professional licensing authority of the province in which the pharmacist or practitioner is registered and entitled to practise in which the authority consents to the retraction of the notice.

  • SOR/2010-223, s. 40
  • SOR/2019-170, s. 16

Marginal note:Communication of information by Minister to licensing authority

  •  (1) The Minister must provide in writing any factual information about a pharmacist, practitioner or nurse that has been obtained under the Act or these Regulations to the provincial professional licensing authority that is responsible for the registration and authorization of the person to practise their profession

    • (a) in the province in which the person is or was registered and entitled to practise if

      • (i) the authority submits a written request that sets out the name and address of the person, a description of the information being requested and a statement that the information is required for the purpose of assisting a lawful investigation by the authority, or

      • (ii) the Minister has reasonable grounds to believe that the person has

        • (A) contravened a rule of conduct established by the authority,

        • (B) been convicted of a designated substance offence, or

        • (C) contravened these Regulations; or

    • (b) in a province in which the person is not registered and entitled to practise, if the authority submits to the Minister

      • (i) a written request that sets out the person’s name and address and a description of the information being requested, and

      • (ii) a document that shows that

        • (A) the person has applied to that authority to practise in that province, or

        • (B) the authority has reasonable grounds to believe that the person is practising in that province without being authorized to do so.

  • Marginal note:Definition of nurse

    (2) For the purpose of subsection (1), nurse does not include a nurse practitioner.

  • SOR/2010-223, s. 41
  • SOR/2019-170, s. 16

Notification of Application for Order of Restoration

Marginal note:Written notification

  •  (1) For the purpose of subsection 24(1) of the Act, notification of an application for an order of restoration must be given in writing to the Attorney General by registered mail and must be mailed not less than 15 days before the date on which the application is to be made to a justice.

  • Marginal note:Content of notification

    (2) The notification must specify

    • (a) the name of the justice to whom the application is to be made;

    • (b) the time and place at which the application is to be heard;

    • (c) details concerning the targeted substance or other thing in respect of which the application is to be made; and

    • (d) the evidence on which the applicant intends to rely to establish that they are entitled to possession of the targeted substance or other thing referred to in paragraph (c).

  • SOR/2019-170, s. 16

Permit for Transit or Transhipment

Marginal note:Application

  •  (1) If a targeted substance is to be shipped from a country of export to a foreign country by a route that requires it to be in transit through Canada or to be transhipped in Canada, the exporter in the country of export or their agent or mandatary in Canada must obtain a permit for the transit or transhipment of the targeted substance by submitting to the Minister an application that contains the following information:

    • (a) the name, municipal address and telephone number of the exporter in the country of export;

    • (b) the name, municipal address and telephone number of the person who will be responsible for the targeted substance while it is in Canada;

    • (c) with respect to the targeted substance,

      • (i) its specified name and, if applicable, its brand name,

      • (ii) if it is a salt, the name of the salt,

      • (iii) its quantity, and

      • (iv) in the case of a raw material, its purity and its anhydrous content;

    • (d) the expected date of transit or transhipment in Canada;

    • (e) the name of the customs office where the importation or exportation is anticipated;

    • (f) each proposed mode of transportation in Canada; and

    • (g) in the case of a transhipment, the municipal address of every place in Canada at which the targeted substance will be stored during the transhipment and the expected duration of the storage at each place.

  • Marginal note:Documents

    (2) The application must be accompanied by

    • (a) a copy of the export permit issued by the competent authority in the country of export; and

    • (b) a copy of the import permit issued by the competent authority in the country of final destination.

  • Marginal note:Signature and attestation

    (3) The application must

    • (a) be signed and dated by a person who is authorized for that purpose by the exporter, including an agent or mandatary in Canada of that exporter; and

    • (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge.

  • Marginal note:Additional information and documents

    (4) The applicant must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2019-170, s. 16

Marginal note:Issuance

  •  (1) Subject to subsection (2), on completion of the review of the application for a permit for transit or transhipment, the Minister must issue to the applicant a permit for transit or transhipment that contains

    • (a) the name, municipal address and telephone number of the exporter in the country of export;

    • (b) the name, municipal address and telephone number of the person who is responsible for the targeted substance while it is in Canada;

    • (c) the specified name of the targeted substance, its quantity, its purity and, if applicable, its strength per unit, the number of units per package and the number of packages;

    • (d) the countries of export and final destination and the numbers and expiry dates of the export and import permits issued by the competent authority in each of those countries;

    • (e) the expected date of the transit or transhipment in Canada;

    • (f) the name of the customs office where the importation or exportation is anticipated;

    • (g) each proposed mode of transportation in Canada;

    • (h) in the case of a transhipment, the municipal address of every place in Canada at which the targeted substance will be stored during the transhipment and the expected duration of the storage at each place; and

    • (i) the dates of issuance and expiry of the permit.

  • Marginal note:Refusal

    (2) The Minister must refuse to issue a permit for transit or transhipment if the Minister has reasonable grounds to believe that

    • (a) the issuance of the permit

      • (i) would contravene an international obligation,

      • (ii) would contravene the Act, the regulations or another Act of Parliament or a law of the country of export, of the country of final destination or of a country of transit or transhipment, or

      • (iii) would likely create a risk to public health or safety, including the risk of the targeted substance being diverted to an illicit market or use; or

    • (b) the import permit issued by the competent authority in the country of final destination has expired or has been suspended or revoked.

  • SOR/2019-170, s. 16

SCHEDULE 1(Subsection 1(1) and section 3)

PART 1

List of Class 1 Targeted Substances

ItemName
1
  • Benzodiazepines, their salts and derivatives, including
    • (1) 
      Alprazolam (8-chloro-1-methyl-6-phenyl-4H — s-triazolo[4,3-a][1,4]benzodiazepine)
    • (2) 
      Bromazepam (7-bromo-1,3-dihydro-5-(2-pyridyl) — 2H-1,4-benzodiazepin-2-one)
    • (3) 
      Brotizolam (2-bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine)
    • (4) 
      Camazepam (7-chloro-1,3-dihydro-3-(N,N-dimethylcarbamoyl) — 1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • (5) 
      Chlordiazepoxide (7-chloro-2-(methylamino)-5 — phenyl-3H-1,4-benzodiazepine-4-oxide)
    • (6) 
      Clobazam (7-chloro-1-methyl-5-phenyl-1H-1,5 — benzodiazepine-2,4(3H,5H)-dione)
    • (7) 
      Clonazepam (5-(o-chlorophenyl)-1,3-dihydro-7 — nitro-2H-1,4-benzodiazepin-2-one)
    • (8) 
      Clorazepate (7-chloro-2,3-dihydro-2,2-dihydroxy — 5-phenyl-1H-1, 4-benzodiazepine-3-carboxylic acid)
    • (9) 
      Cloxazolam (10-chloro-11b-(o-chlorophenyl)-2,-3,7,11b-tetrahydrooxazolo [3,2-d][1,4]benzodiazepin-6[5H]-one)
    • Delorazepam (7-chloro-5-(o-chlorophenyl)-1,3-dihydro-2H-1,-4-benzodiazepin-2-one)
    • Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Estazolam (8-chloro-6-phenyl-4H-s-triazolo[4,3-a] — [1,4]benzodiazepine)
    • Ethyl Loflazepate (ethyl 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,-4-benzodiazepine-3-carboxylate)
    • Fludiazepam (7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one)
    • Flurazepam (7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
    • Halazepam (7-chloro-1,3-dihydro-5-phenyl-1-(2,2,-2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one)
    • Haloxazolam (10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydro-oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one)
    • Ketazolam (11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]-oxazino-[3,2-d][1,4]benzodiazepine-4,7(6H)-dione)
    • Loprazolam (6-(o-chlorophenyl)-2,4-dihydro-2-[(4--methyl-1-piperazinyl)methylene]-8-nitro-1H-imidazo[1,2-a] [1,4]-benzodiazepin-1-one)
    • Lorazepam (7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one)
    • Lormetazepam (7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one)
    • Medazepam (7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine)
    • Midazolam (8-chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine)
    • Nimetazepam (1,3-dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Nitrazepam (1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Nordazepam (7-chloro-1,3-dihydro-5-phenyl — 2H-1,4-benzodiazepin-2-one)
    • Oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Oxazolam (10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one)
    • Pinazepam (7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-2H-1,-4-benzodiazepin-2-one)
    • Prazepam (7-chloro-1-(cyclopropylmethyl)-1,3-di-hydro-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Quazepam (7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione)
    • Temazepam (7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one)
    • Tetrazepam (7-chloro-5-(cyclohexen-1-yl)-1,3-di-hydro-1-methyl-2H-1,4-benzodiazepin-2-one)
    • Triazolam (8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo-[4,3-a][1,4]benzodiazepine)
    • but not including
    • Clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine) and any salt thereof
    • Flunitrazepam (5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one) and any salts or derivatives thereof
    • Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) and its salts
    • Clozapine N-oxide (8-chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine) and its salts
2Clotiazepam (5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2-H-thieno[2,3-e]-1,4-diazepin-2-one) and any salt thereof
3Ethchlorvynol (ethyl-2-chlorovinyl ethynyl carbinol)
4Ethinamate (1-ethynylcyclohexanol carbamate)
5Fencamfamin (d,l-N-ethyl-3-phenylbicyclo[2,2,1]-heptan-2-amine) and any salt thereof
6Fenproporex (d,l-3-[(α-methylphenethyl)amino]propionitrile) and any salt thereof
7Mazindol (5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol)
8Mefenorex (d,l-N-(3-chloropropyl)-α-methylbenzene-ethanamine) and any salt thereof
9Meprobamate (2-methyl-2-propyl-1,3-propanedioldicarbamate)
10Methyprylon (3,3-diethyl-5-methyl-2,4-piperidinedione)
11Pipradrol (α,α-diphenyl-2-piperidinemethanol) and any salt thereof
12Zolpidem (N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide) and any salt thereof

PART 2

List of Class 2 Targeted Substances

ItemName
1Flunitrazepam (5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one) and any salts or derivatives thereof
  • SOR/2003-38, s. 3
  • SOR/2017-12, ss. 10, 11
  • SOR/2019-170, s. 17

SCHEDULE 2(Subsection 1(1))

Specified Names of Targeted Substances

ItemColumn 1Column 2
Specified NameChemical Name
1Alprazolam8-chloro-1-methyl-6-phenyl-4H — s-triazolo[4,3-a][1,4]benzodiazepine
2Bromazepam7-bromo-1,3-dihydro-5-(2-pyridyl) — 2H-1,4-benzodiazepin-2-one
3Brotizolam2-bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine
4Camazepam7-chloro-1,3-dihydro-3-(N,N-dimethylcarbamoyl) — 1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
5Chlordiazepoxide7-chloro-2-(methylamino)-5 — phenyl-3H-1,4-benzodiazepine-4-oxide
6Clobazam7-chloro-1-methyl-5-phenyl-1H-1,5 — benzodiazepine-2,4(3H,5H)-dione
7Clonazepam5-(o-chlorophenyl)-1,3-dihydro-7 — nitro-2H-1,4-benzodiazepin-2-one
8Clorazepate7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
9Cloxazolam10-chloro-11b-(o-chlorophenyl)-2,-3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6[5H]-one
10Delorazepam7-chloro-5-(o-chlorophenyl)-1,3-dihydro-2H-1,-4-benzodiazepin-2-one
11Diazepam7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
12Estazolam8-chloro-6-phenyl-4H-s-triazolo[4,3-a] — [1,4]benzodiazepine
13Ethyl Loflazepateethyl 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,-4-benzodiazepine-3-carboxylate
14Fludiazepam7-chloro-5-(o-fluorophenyl)-1,3-di-hydro-1-methyl-2H-1,4-benzodiazepin-2-one
15Flurazepam7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
16Halazepam7-chloro-1,3-dihydro-5-phenyl-1-(2,2,-2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one
17Haloxazolam10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydro-oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one
18Ketazolam11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]-oxazino-[3,2-d][1,4]benzodiazepine-4,7(6H)-dione
19Loprazolam6-(o-chlorophenyl)-2,4-dihydro-2-[(4--methyl-1-piperazinyl)methylene]-8-nitro-1H-imidazo[1,2-a][1,4]-benzodiazepin-1-one
20Lorazepam7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one
21Lormetazepam7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one
22Medazepam7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine
23Midazolam8-chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
24Nimetazepam1,3-dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
25Nitrazepam1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
26Nordazepam7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
27Oxazepam7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one
28Oxazolam10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one
29Pinazepam7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-2H-1,-4-benzodiazepin-2-one
30Prazepam7-chloro-1-(cyclopropylmethyl)-1,3-di-hydro-5-phenyl-2H-1,4-benzodiazepin-2-one
31Quazepam7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione
32Temazepam7-chloro-1,3-dihydro-3-hydroxy-1methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
33Tetrazepam7-chloro-5-(cyclohexen-1-yl)-1,3-di-hydro-1-methyl-2H-1,4-benzodiazepin-2-one
34Triazolam8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo-[4,3-a][1,4]benzodiazepine
35Clotiazepam5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2-H-thieno[2,3-e]-1,4-diazepin-2-one
36Ethchlorvynolethyl-2-chlorovinyl ethynyl carbinol
37Ethinamate1-ethynylcyclohexanol carbamate
38Fencamfamind,l-N-ethyl-3-phenylbicyclo[2,2,1]-heptan-2-amine
39Fenproporexd,l-3-[(α-methylphenethyl)amino]propionitrile
40Flunitrazepam3(5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one
41Mazindol5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol
42Mefenorexd,l-N-(3-chloropropyl)-α-methylbenzene-ethanamine
43Meprobamate2-methyl-2-propyl-1,3-propanedioldicarbamate
44Methyprylon3,3-diethyl-5-methyl-2,4-piperidinedione
45Pipradrolα,α-diphenyl-2-piperidinemethanol
46ZolpidemN,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide
  • SOR/2003-38, s. 4
  • SOR/2017-12, s. 11
Date modified: